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Abstract

RELATIONSHIP OF MITOCHONDRIAL ENZYMES TO FATIGUE INTENSITY AND
HEALTH-RELATED QUALITY OF LIFE IN MEN WITH PROSTATE CANCER
RECEIVING EXTERNAL BEAM RADIATION THERAPY
By Kristin A. Filler, PhD, RN
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2014.
Major Director: Nancy L. McCain, PhD, RN, FAAN
Nursing Alumni Distinguished Professor, Adult Health and Nursing Systems, School of Nursing

Introduction: Cancer-related fatigue is often described by patients as a lack of energy, mental or
physical tiredness, diminished endurance, and prolonged recovery after activity. Etiologic
mechanisms underlying CRF are not well understood.
Methods: A literature review was conducted to examine studies that had investigated the
association of mitochondrial dysfunction with fatigue. The major conclusion from this review
was that alterations in energy metabolism may contribute to fatigue. Therefore, the dissertation
study focused on laboratory techniques for measuring mitochondrial oxidative phosphorylation
enzymes (complexes I-V) and a mitochondrial-specific oxidative stress marker (superoxide
dismutase 2 [SOD2]). The primary aim of the dissertation research was to describe levels of
biomarkers of mitochondrial function, fatigue, and health-related quality of life (HRQOL) before
and at the completion of external beam radiation therapy (EBRT) in men with nonmetastatic

prostate cancer (NM-PC). To achieve this aim a secondary analysis of a descriptive, longitudinal
study was conducted (#10-NR-0128).
Results: A total of n = 22 men with NM-PC were included in this study. There were significant
increases in fatigue and a significant decrease HRQOL from baseline to the completion of
EBRT. However, there was no significant change in the biomarkers of mitochondrial function
from baseline to EBRT completion. Given the exploratory nature of the study, it was decided to
further investigate the patient sample to understand the relationship of fatigue and mitochondrial
function in a well-characterized fatigue phenotype. There was preliminary evidence to support
the possibility of distinct patterns of mitochondrial enzyme levels between those with a high
intensification of fatigue and those with a low intensification of fatigue during EBRT; however,
these differences were not statistically significant.
Discussion: To our knowledge, this is the first study to describe the relationship between
mitochondrial enzymes and fatigue before and during EBRT in men with NM-PC. The most
important preliminary finding from this study is the possibility that mitochondrial enzymes might
be related to fatigue intensification during EBRT. Future studies will be critical to determine if
these preliminary findings are replicable, and if so, whether there are potential therapeutic targets
in individuals at highest risk for fatigue intensification during EBRT.

Chapter One

My experience as an oncology nurse has exposed me to the clinical issues surrounding
quality of life in patients with cancer, especially those issues surrounding symptom management.
My experiences as both a doctoral student and research assistant have provided me with the
knowledge and theoretical foundation in which to conduct symptom mechanism and
biobehavioral research in the oncology population. An enhanced understanding of the etiology of
symptoms can lead to the development of more targeted and individualized management
strategies to improve health-related quality of life in this population.
My dissertation research focused on understanding the role that mitochondria might play
in the development of cancer-related fatigue during external beam radiation therapy. To identify
areas needing further research, a review of the literature was conducted to examine markers of
mitochondrial function that may have an association with fatigue in order. Dysfunctions in the
mitochondrial structure, mitochondrial function (as indicated by mitochondrial enzymes and
oxidative/nitrosative stress), mitochondrial energy metabolism (ATP production and fatty acid
metabolism), immune response, and genetics were investigated as potential contributors to
fatigue. A detailed description of this literature review was published in the journal BBA
Clinical and is presented as Chapter Two.
The findings from this literature review guided the development of the dissertation
proposal. The primary aim of the dissertation research was to describe levels of biomarkers of
1

mitochondrial function, fatigue, and health-related quality of life (HRQOL) before and at the
completion of EBRT in men with nonmetastatic prostate cancer. The specific aims were to: (1)
describe levels of biomarkers of mitochondrial function (mitochondrial oxidative
phosphorylation enzymes [complexes I-V] and the antioxidant manganese superoxide dismutase
2 [MnSOD2]), fatigue and HRQL before and at completion of EBRT, and (2) examine
relationships over time in levels of biomarkers of mitochondrial function, fatigue, and HRQOL.
Following the initial analyses, an exploratory aim evolved to compare levels of biomarkers of
mitochondrial function in men with little increase in fatigue from baseline to completion of
EBRT to those with greater increases in fatigue from baseline to completion of EBRT.
There were significant increases in fatigue and a significant decrease in HRQOL from
baseline to the completion of EBRT; however, there were no significant differences in
mitochondrial enzymes from baseline to completion of EBRT. Due to the exploratory nature of
this study, the participant sample was then categorized based upon their fatigue intensification
during EBRT. Once categorized, we found preliminary evidence to support the possibility of
patterns of mitochondrial enzyme levels between the two fatigue groups; however, these
differences were not statistically significant. A detailed description of this dissertation research is
presented as Chapter Three.
To our knowledge, this is the first study that explored measures of mitochondrial enzyme
function in relationship to fatigue prior to and at the completion of EBRT in men with prostate
cancer. Future studies will be critical to determine if these preliminary findings are replicable,
and if so, whether there are potential therapeutic targets in individuals at highest risk for fatigue
intensification during EBRT, in order to optimize fatigue management and improve HRQOL.
Future directions for this line of research are discussed in Chapter Four.
2

Chapter Two

1. Introduction
Mitochondria are increasingly recognized as major contributors to human health and
disease because of their location and influence (Cohen & Gold, 2001). Mitochondria have an
essential role in energy production through the process of oxidative phosphorylation where
nutrients are converted into adenosine triphosphate (ATP), which powers many of the cells’
activities. In addition to energy production, mitochondria have been implicated in various
physiologic processes including the production of reactive oxygen species (ROS), pyrimidine
and lipid biosynthesis, regulation of cellular levels of substrates (amino acids, metabolites,
enzyme cofactors), apoptosis, metal (Fe-S cluster and heme) metabolism, calcium homeostasis
and flux, neurotransmitter synthesis, heat production, and insulin secretion (Duchen, 2004;
Nunnari & Suomalainen, 2012; Pieczenik & Neustadt, 2007). Therefore, damage to
mitochondria can have widespread consequences (Duchen, 2004).
Health conditions such as cancer, diabetes, fibromyalgia, and serious mental disorders
such as schizophrenia and bipolar disease are also proposed to result from mitochondrial
dysfunction, though the links are less clear (Pieczenik & Neustadt, 2007; Reynolds, 2007).
Mechanisms underlying mitochondria–related disease states have predominantly focused on
DNA damage and ROS generation (Cohen & Gold, 2001; Pieczenik & Neustadt, 2007).
Mitochondrial dysfunction can be of primary (inherent) or secondary (acquired dysfunction)
3

origin (Cohen & Gold, 2001; Read & Calnan, 2000). Primary dysfunction results from
mitochondrial DNA (mtDNA) mutations inherited from mothers, who are the sole contributors
of mitochondria to their offspring (Cohen & Gold, 2001). Mitochondrial DNA has a much higher
mutation rate than nuclear DNA because it lacks protective histones (Read & Calnan, 2000), is
readily exposed to damage from ROS production (Alexander et al., 2010; Pieczenik & Neustadt,
2007; Reynolds, 2007), and lacks certain DNA repair mechanisms (Cohen & Gold, 2001).
Secondary mitochondrial dysfunction results from the influence of external mechanisms such as
environmental or pharmacologic toxins that can damage the mtDNA (Cohen & Gold, 2001).
Mitochondria can protect themselves from the accumulation of damage through various quality
control mechanisms (e.g., fission and fusion) (Nunnari & Suomalainen, 2012; Youle & van der
Bliek, 2012); however, if these mechanisms are altered, mitochondrial dysfunction can lead to
disease (Blackstone & Chang, 2011; Duchen, 2004). Past research has predominantly focused on
the role of mitochondrial dysfunction on disease pathology. However, some studies have
investigated how mitochondrial dysfunction is associated with the development of distressing
symptoms such as fatigue, neuropathic pain, weakness, and depression (Pieczenik & Neustadt,
2007); however, these investigations are still in their infancy. This paper reviewed studies that
investigated the association of mitochondrial dysfunction with fatigue.
Fatigue is a hallmark symptom of mitochondrial disease. Fatigue is often described by
patients as a lack of energy, mental or physical tiredness, diminished endurance, and the need for
a prolonged recovery after physical activity (Rosenthal, Majeroni, Pretorius, & Malik, 2007).
Fatigue is reported by patients to be unrelieved by rest (Jason, Evans, Brown, & Porter, 2010;
Rosenthal et al., 2008). As pervasive and debilitating as fatigue is, the etiology of fatigue
remains poorly understood. Without a known pathophysiological mechanism for fatigue, there is
4

minimal consistency in its clinical definition (Alexander et al., 2010; Hardy & Studenski, 2010;
Jason et al., 2010; Swain, 2000). Furthermore, the lack of a proper clinical definition of fatigue
contributes to its underdiagnosis and poor management, which in turn contributes to increased
symptom burden and poorer quality of life in patients with fatigue (Norheim, Jonsson, & Omdal,
2011). The purpose of this systematic review was to examine markers of mitochondrial function
( in adults) that have evidence of an association with fatigue in order to identify areas needed for
further research. In this paper markers of mitochondrial function that associate with fatigue in
adult patients were reviewed in order to describe empirical evidence of a relationship between
mitochondrial dysfunction and fatigue and to propose possible research directions that would
enhance understanding of the role of mitochondrial dysfunction in fatigue.
2. Methods
An initial literature query was conducted in the following four reference databases using
search strategies as summarized in Table 1. The initial search resulted in 2,055 articles. After
removing duplicates, the abstracts of 1,220 articles were assessed for relevance to the area of
interest. Abstracts that discussed the association of markers of mitochondrial function and
fatigue were selected to be included in this review. In addition, studies were excluded if they
were more than 20 years old, were not original research, were animal or cell-based studies,
investigated the effect of medication or treatment on fatigue, mitochondrial markers or both, or
measured induced fatigue through the use of exercise or electric stimulation. Also excluded were
letters, literature reviews, notes, conference or meeting abstracts, book chapters, editorials,
dissertations, case reports or series, short reports, workshop reports, and practice guidelines. A
total of 54 articles were selected for full-text review. Of these, 25 were excluded based upon the
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aforementioned criteria, 3 were excluded because they focused on neuroimaging, and 1 was
excluded because it included children. A total of 25 articles were selected for full review.
Table 1. Search Criteria
Database
Search Terms
mitochondria
OR mitochondrial AND
PubMed
Scopus

Web of Science
Embase

fatigue
(TITLE(mitochondria OR mitochondrial)
AND TITLE(fatigue))
(TITLE(mitochondria OR mitochondrial)
AND TITLE(fatigue))
Topic=(mitochondria OR mitochondrial)
AND Topic=(fatigue)
'fatigue'/exp AND ('mitochondrion'/exp
OR 'mitochondrial respiration'/exp OR
'mitophagy'/exp OR 'mitochondrial
dna'/exp OR 'disorders of mitochondrial
functions'/exp OR 'mitochondrial
dynamics'/exp OR 'mitochondrial energy
transfer'/exp OR 'mitochondrial
enzyme'/exp OR 'mitochondrial gene'/exp
OR 'mitochondrial genome'/exp OR
'mitochondrial membrane potential'/exp
OR 'mitochondrial protein'/exp OR
'mitochondrion swelling'/exp)

Filters
Humans
English
English

Yield
N=358

English

N=624

Humans
English

N=554

N=519

3. Results
Twelve of the 25 articles (48%) were published within the last five years. Twenty-two
(88%) of the studies used a cross-sectional design; three used a repeated-measures design.
Eighteen studies investigated only patients with chronic fatigue syndrome (CFS); remaining
studies investigated a combination of myalgic encephalomyelitis (ME) and CFS (n=2), ME
(n=1), multiple sclerosis (n=1), HIV-related fatigue (HRF) (n=1), systemic lupus erythematosus
(SLE) (n=1), and cancer-related fatigue (CRF) (n=1). One study restricted participant gender and
included only males (Hsiao, Wang, Kaushal, & Saligan, 2013). A complete description of study
attributes are found in Tables 2 and 3.
6

Table 2. Studies Investigating Mitochondrial Dysfunction in CFS and/or ME
Authors
Edwards,
et al.
(1993).

Study
Design
crosssectional,
descriptive

Sample
Characteristics
n= 74 CFS
patients

Fatigue
Definition
not
specified

Fatigue
Measurement
CFS diagnosis
(criteria/guidelines
not specified)

Controls:
a. n= 34
patients
with myalgia
b. n= 22

Kuratsune,
et al.
(1994).

crosssectional,
descriptive

asymptomatic
controls
n= 38 CFS
patients

Mitochondrial
Marker
Assessed
1.
mitochondrial
hyperplasia
2. cytochrome
c
oxidase

CDC 1988
criteria

CFS diagnosis
according to CDC
criteria

Controls:
n= 308 healthy
volunteers

3.
myoadenylate
deaminase
1. free Lcarnitine

Sample
Source

Association to Fatigue

muscle
biopsy from
either:
a. tibialis
anterior
b.
quadriceps
c. gastrocnemius, medial
head

No significant
differences between CFS
patients and controls.

serum

Free L-carnitine levels
lower in male CFS
patients and higher in
female CFS compared to
controls; however, not
statistically significant.

2. acylcarnitine

Acylcarnitine levels
lower (p < .001) in CFS
patients compared to
controls.

Behan et
al. (1995).

Plioplys et
al. (1995a).

crosssectional,
descriptive

crosssectional

n= 31 CFS
patients
Controls:
n= 20
volunteers with
no muscle
disease
n= 15 CFS
patients
Controls:
n= 15; age and
sex-matched
healthy
volunteers

CDC 1988
criteria

CFS diagnosis
according to CDC
criteria

1. histological
2.
histochemical

vastus
lateralis
muscle
biopsy

In CFS patients, lower
acylcarnitine levels
associated with worse
performance and
increased symptom
burden at initial exam.
Upon symptom
improvement,
acylcarnitine levels
increased (p < .02).
Size and morphology of
mitochondria showed
differences between CFS
and controls. No
statistical data provided.

3.
ultrastructural
1. CDC
1988 &
1994
criteria
2. British &
Australian
definitions
for CFS

1. Fatigue
Severity Scale
(FSS)

ultrastructural
exam of
mitochondria

right vastus
lateralis
muscle
biopsy

No significant
differences upon
structural exam between
CFS patients and
controls.

carnitine levels

serum

Negative association
between acylcarnitine
levels and CFS-II mental
index score (r = -0.761, p
< 0.01) and total score (r
= -0.634, p < 0.05).

2. Beck
Depression
Inventory (BDI)
3. Symptom
Checklist 90-R
4. CFS
Impairment Index
(CFS-II).
5. Structural
Clinical Interview
for the DSM IIIR-Nonpatient
Edition
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Plioplys et
al. (1995b).

crosssectional

n= 35 CFS
patients

CDC 1988
criteria

1. FSS

carnitine
levels: total,
free,
aceylcarnitine

2. BDI
Controls:
a. Mayo clinic
normative
data
(n=85)
b. historical
study
(Kuratsune,
et
al. 1994.)

serum

3. Symptom
Checklist 90-R

Total carnitine lower in
female (p < .001) and
male (p < .05) CFS
patients compared to
Mayo clinic data.
Free carnitine lower in
female (p < .01) and
male (p < .05) CFS
patients compared to
Mayo clinic data.

4. CFS-II.

Acylcarnitine lower in
CFS patients compared to
historical study controls
(p < .00001).
Free carnitine lower in
CFS patients compared to
historical controls (p <
.00001).
Total carnitine lower in
CFS patients compared to
historical controls (p <
.00001).
Free carnitine correlated
with CFS-II physical
impairment subset (r =
.412, p < .05).
Negative correlation
between FSS and free
carnitine (r = -.496, p =
.02), and total carnitine
and FSS (r = -.473, p =
.02).

McArdle et
al. (1996).

Behan et
al. (1999).

crosssectional

crosssectional

n= 54 CFS
patients only
included n= 34
for viral
analysis
Controls:
a. for enzyme
comparison
n = 16 from
a
previous
study
b. for RNA
detection
n= 10
patients
undergoing
orthopedic
surgery; no
muscle
damage
or fatigue.
n= 16 CFS
patients

1. diagnosis
with CFS
on the basis
of
complaints
of muscle
pain and
fatigue

Not mentioned

2. diagnosis
conformed
to the
Oxford
Consensus
Criteria

CDC 1994
criteria.

1.
mitochondrial
enzymes:
a. citrate
synthase
b. succinate
reductase
c.
cytochrome-c
oxidase

anterior
tibialis
muscle
biopsy

2. presence of
enteroviral
RNA

CFS diagnosis
according to CDC
criteria

Controls:
n =10 healthy
volunteers
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1. Aerobic
capacity
a. pyruvate
b. lactate
c. L/P ratio
d.

Reduction in all 3
mitochondrial enzyme
activities (p < .05) in
CFS patients compared to
control values from a
previous study.

Failed to detect evidence
of enteroviral RNA.

Right or left
vastus
lateralis
muscle
biopsy

Increased pyruvate levels
in CFS patients (p =
.053).
All other biological
parameters showed no

respiratory
capacity
e.
cytochromec oxidase
f. LDH

significant findings
between the groups.

2. DNA
analysis
a. total
mtDNA
volume
b. mtDNA
rearrangements
c. point
mutation
at
nucleotide
pair 3243
d. two
deletions:
mtDNA
4977
mtDNA
7436

Soetekouw
et al.
(2000).

crosssectional

n= 25
Caucasian,
female CFS
patients
Controls:
n= 25 age- and
sex- matched
healthy
volunteers

Kurup et
al. (2003b).

crosssectional

n= 15 CFS
patients
Controls:

1. CDC
1994
criteria.

1. Checklist
Individual Strength
(CIS)

2. Fatigue
with
substantial
ADL
impairment:
a. a score
of
35+ on
the
Checklist
Individual
Strength

2. Sickness Impact
Profile (SIP)

subjective
fatigue
subscale
b. a score
of
750+ on
the
weighted
total
score
of the
Sickness
Impact
Profile.
CDC
criteria

3. Histological,
Histochemical,
and
Ultrastructural
examination
1. carnitine
levels: total,
free, &
acylcarnitine

serum

2. carnitine
ester profiles

CFS patients were more
fatigued (p < .001) and
had more functional
impairment (p < .001) as
determined by
questionnaires.
No significant
differences with any of
the biologic markers
between the groups.

structured clinical
interview to assess
CFS and comorbid
conditions
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Mitochondrial
markers:
1. ubiquinone
2. ROS/RNS

RBCs and
plasma/serum

1. Ubiquinone lower in
CFS patients (F = 259.36,
p < .01)

n= 45 age and
sex-matched
healthy
volunteers

Kaushik et
al. (2005).

repeated
measures:
two time
points 6
months apart
during which
symptoms did
not vary
significantly

n= 25 CFS
patients

a. MDA
b.
Hydroperoxide
c.
conjugated
dienes
d. NO
3. antioxidants
a.
glutathione
b. SD
c. catalase
d. GSH
peroxidase
e. GSH
reductase

CDC 1994
criteria.

Controls:
1. Microarray,
n= 25 age- and
sex- matched
normal blood
donors

1. diagnosis of
CFS according to
CDC criteria

Real-time
PCR

2. Chalder Fatigue
Scale

Peripheral
blood
mononuclear
cells
(PBMCs)

3 up-regulated genes are
located in the
mitochondria:
a. EIF2B4
(p = 1.8 x 10-5)
b. EIF4G1
(p = 7.63 x 10-13)
c. MRPL23
(p = 1.25 x 10-6)

2. Real-time
PCR, n =21
age- and sexmatched normal
blood donors

Vernon et
al. (2006).

repeated
measures:
baseline,
2-3 weeks,
4-6 weeks,
3 months,
6 months (in
those with
symptoms),
& 12 months.

n= 5 with
symptoms
suggestive of
infectious
mononucleosis
with
provisional lab
confirmation

CDC 1994
criteria

1. diagnosis of
CFS according to
CDC criteria
2. self-report and
interview
assessment of
psychological and
physical health.

Controls:
n= 5 controls
that recovered
promptly from
infectious
mononucleosis;
HLA –A and B, sex, and agematched.

2. ROS markers higher in
CFS patients
a. MDA
(F= 4.56, p < 0.05)
b. Hydroperoxide
(F= 3.25, p < 0.05)
c. conjugated dienes
(F= 16.21, p < 0.01)
d. NO
(F= 6.54, p < 0.05)
3. Antioxidants lower in
ME patients
a. glutathione
(F= 8.36, p < 0.05)
b. SD
(F= 7.56, p < 0.05)
c. catalase
(F= 3.98, p < 0.05)
d. GSH peroxidase
(F= 11.26, p < 0.01)
e. GSH reductase
(F= 4.26, p < 0.05)
16 genes differentially
expressed in CFS patients
(15 genes up-regulated, 1
down-regulated).

gene
transcription
patterns

PBMCs

2 up-regulated genes for
peroxisomal function,
ABCD4 (p = .00190 and
PEX16 (p = .0126),
suggesting enhanced
defense to oxidative
damage.
Due to small n in each
group, data was
categorized by time
periods: early (baseline-3
months) and late (> 6
months following disease
onset).
Early Phase:
23 genes differentially
expressed between cases
and controls; 8 expressed
in cases and involved
binding and metabolism
ontologies.
Early & Late Phase:
24 genes significantly
different between cases
and controls; 12 genes
are associated with
mitochondrial function.
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Hokama et
al. (2008).

crosssectional

n= 328 CFS
patients

CDC 1994
criteria

CFS diagnosis
according to CDC
criteria

n= 18 CCFP
patients

1.
Phospholipids

serum

2. Anticardiolipin
(aCL)
antibodies

n= 8 GWVs

CFS, CCCP, GWV, and
PC patients have
cardiolipin associated
with mitochondrial
membrane.
The presence of aCL was
also detected.

n= 15 PC
patients

Hokama et
al. (2009).

Maes et al.
(2009b).

crosssectional

crosssectional

n= 49 normal,
healthy controls
n= 40 CFS
patients

n= 35 major
depressed
patients; n= 17
patients had a
diagnosis with
CFS
Controls:
n= 22 healthy
volunteers

CDC 1994
criteria

CFS diagnosis
according to CDC
criteria

Anticardiolipin
antibodies

serum

1. 1994
CDC
criteria

1. CFS diagnosis
according to CDC
criteria

CoQ10 levels

plasma

2. Criteria:
a. severe
chronic
fatigue
for at
least 6
months
b. at least 4

2. Fibromyalgia
and CFS Rating
Scale (FF scale)

IgM isotope present in
95% of CFS patients. IgG
isotype present in 10%
and the IgA isotype
present in 5% of CFS
patients.
Depressed patients with
CFS had lower plasma
CoQ10 than depressed
patients without CFS (F
= 8.7, df = 1/33, p =
.006).
CFS independently
predicted low CoQ10
values (F = 4.3, df =
1/31, p = .04).

additional

Myhill, et
al. (2009)

crosssectional

n= 71 CFS
patients

symptoms
from a
checklist
CDC 1994
criteria

Controls:
n= 53 normal,
healthy
volunteers

1. CFS diagnosis
according to CDC
criteria
2. CFS Ability
Scale

1. "ATP
Profile" test:
a. ATP
concentration
and ATP
ratio
b. The
efficiency of
ox-phos
process
c.
Translocator
(TL) protein
function
(TL-OUT
and TLIN)

neutrophils

Patients grouped into 3
groups based on CFS
Ability Scale scores: very
severe (VS), severe (S),
and moderate (M).
For most of the 5 factors
of the “ATP Profile Test”
the percentage of patients
who are in the normal
region increases from
VS, S, to M.
The MES is highly
correlated with the CFS
Ability scale (R2 = .645,
p < .001).

2.
Mitochondrial
Energy Score
(MES)
Pietrangelo
et al.
(2009).

crosssectional

n= 4 CFS
patients
n= 2 female
patients,
meeting CDC
criteria
n= 2 male
patients

CDC 1994
criteria

1. CFS diagnosis
according to CDC
criteria
2. skeletal
muscle
membrane
testing
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Global
transcriptome
analysis

aaRNA
obtained
from
vastus
lateralis
muscle
biopsy

47 genes significantly
altered in CFS patients: 2
up-regulated, 38 downregulated and 7 upregulated in females, but
down-regulated in males.
Gene Pathways:

meeting CDC
criteria for CFS

Control of Ox-Phos; 3
mitochondrial genes were
down-regulated: SOD2,
FDX1, and NQO1.

Controls:
n= 9 healthy
volunteers

Reuter, et al.
(2011).

crosssectional

n= 44 CFS
patients
Controls:
n= 49 age and
gender-matched
healthy subjects

Energy Balance;
depressed transcription of
several genes implicated
in the energy
metabolism: PFKFB3,
PDK4, GOT1, AMPD3,
and ATP-binding cassette
member 5. One gene,
VLDLR was up-regulated

Royal
Australasian
College of
Physicians
CFS clinical
practice
guidelines

1. medical
diagnosis of CFS
using the Royal
Australasian
College of
Physicians CFS
clinical practice
guidelines

1. Endogenous
carnitine: total,
L-,
and
acylcarnitine

plasma

2. 35
individual
carnitines

Apoptosis; FOS, MYC,
SOX17, AATF, CEBPD
were all down-regulated.
CFS patients had lower
individual carnitines:
C8:1 (p = .0201), C14 (p
= .0023), C16:1 (p =
.0383), C18 (p = .0104),
C18:1 (p < .0001) , and
C18:2 (p < .0001).
CFS patients had higher
C12DC (p < .0001) and
C18:1-OH (p = .0191).

2. FSS

Negative correlation
between FSS scores and
C8:1, C14, C16:1,
specifically with C18:1
(R = -.3547, p = .0009)
and C18:2 (R = -.4191, p
< .0001).
Significant positive
correlations between
fatigue severity and
C12DC, C16, and C18:1OH.
Smits et al.
(2011).

crosssectional

n= 16 CFS
patients
Controls:
n= 11 male
healthy
volunteers

1. CDC
1994
criteria

1. diagnosis of
CFS according to
CDC criteria

2. Severe
fatigue
determined
as > 35 on
the fatigue
subscale of
the CIS.

2. CIS
3. SIP-8.

1. ATP
production rate
2. Respiratory
chain
complexes
activity
(Complex I,
II+III, II, and
IV)
3. Citrate
Synthase
levels

3. Fatigue
longer than
6 months
4. Fatigue
not
explained
by somatic
or
psychiatric
illness or
ongoing
exertion and
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right
quadriceps
muscle
biopsies

No significant
differences in ATP
production or respiratory
chain complex activity in
CFS patients.
Citrate synthase levels
were lower in CFS
patients (p < .001).

is not
relieved by
rest.
5. myalgia
and/or
exercise
intolerance.

Maes et al.
(2009a).

crosssectional

n= 58 ME/CFS
patients

6.
Substantial
functional
impairment
determined
by a score
of 700+ on
the SIP-8.
1994 CDC
criteria

1. CFS diagnosis

CoQ10 levels

plasma

2. FF scale
Controls:
n= 22 healthy
volunteers

Booth et al.
(2012).

crosssectional

n= 61 ME/CFS
patients (Cohort
1; still ill after
interventions;
from previous
study)
n= 138
ME/CFS
patients (Cohort
2; no prior
interventions)

Plasma CoQ10 lower in
ME/CFS patients (F =
31.0, df = 1/78, p =
.00001)
Negative association
between CoQ10 and total
FF scale score (r = .28, p
= .03).

1. CDC
1994
criteria

1. CFS diagnosis
according to CDC
criteria

2. ICCME
(most, if not
all were
met)

2. the Bell CFS
Ability Scale

Controls:
n= 53 normal,
healthy
volunteers
(Myhill et al.,
2012)
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1. 5 parameters
of the ATP
Profile test:
a. ATPmg
b. ATP end
c. Ox-Phos
d. TL OUT
e. TL IN
2. MES
3. Nfn
4. MESinh

neutrophils

Negative correlation
between CoQ10 and
fatigue (r = -.86, p < 105
).
ME/CFS patients had
reduced ATP production
Mitochondrial
dysfunction, mainly
through partial blockage
of the TL was
demonstrated in both
cohorts.
It was observed that
neutrophils used at least
two different pathways to
compensate for
mitochondrial
dysfunction.

Table 3. Studies Investigating Mitochondrial Dysfunction in Other Fatigued Populations
Authors
Fukazawa et
al. (1996).

Study
Design
crosssectional

Sample
Characteristics

Fatigue
Definition

n= 25 MS
patients; n= 11
with disabling
fatigue and n=
14 without
fatigue

1.
debilitating,
persistent, or
relapsing
fatigue
noted after
the onset of
MS

Controls:
n= 25 age- and
sex-matched
healthy
volunteers

Kurup et al.
(2003a).

crosssectional

n= 15 ME
patients

2. lack of
other causes
of fatigue
based on a
history,
physical
examination,
and
laboratory
tests.
CDC criteria

Controls:
n= 45 age and
sex-matched
healthy
volunteers

Segal et al.
(2012).

crosssectional

n= 71 SLE
patients

not specified

Controls:
n= 51 healthy
volunteers

Fatigue
Measurement
Technique
Medical
diagnosis of
fatigue

Mitochondrial
Dynamic Assessed

Sample
Source

carnitine levels:
total, free, and
acylcarnitine

serum

No significant
differences in carnitine
levels between the
groups.

structured
clinical
interview to
assess CFS
and comorbid
conditions

Mitochondrial
markers:
1. ubiquinone
2. ROS/RNS
a. MDA
b.
Hydroperoxide
c. conjugated
dienes
d. NO
3. antioxidants
a. glutathione
b. SD
c. catalase
d. GSH
peroxidase
e. GSH
reductase

RBCs and
plasma/serum

1. Ubiquinone lower in
ME patients (F = 259.36,
p < .01)

1. Visual
Analogue
Scale-fatigue

F 2 -isoprostane

Plasma

2. FSS

repeated
measures;
Baseline
Day 1,

n= 15 men with
non-metastatic
prostate cancer
receiving ADT

not specified

revised Piper
Fatigue Sale
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2. ROS markers higher
in ME patients
a. MDA
(F= 4.56, p < 0.05)
b. Hydroperoxide
(F= 3.25, p < 0.05)
c. conjugated dienes
(F= 16.21, p < 0.01)
d. NO
(F= 6.54, p < 0.05)
3. antioxidants lower in
ME patients
a. glutathione
(F= 8.36, p < 0.05)
b. SD
(F= 7.56, p < 0.05)
c. catalase
(F= 3.98, p < 0.05)
d. GSH peroxidase
(F= 11.26, p < 0.01)
e. GSH reductase
(F= 4.26, p < 0.05)
SLE patients with
fatigue had higher levels
of F 2 -isoprostane than
non-fatigued SLE
patients (p = .0076).
Positive correlation
between F 2 -isoprostane
and fatigue in SLE
patients.

3. Profile of
Fatigue (ProF)

Hsiao et al.
(2013).

Findings

radiation-induced
changes in
mitochondriarelated gene

WBCs-RNA

F 2 -isoprostane predicts
higher FSS scores in
SLE patients (p = .0002).
Eleven genes related to
mitochondrial function
were differentially
expressed over time

Day 7,
Day 14,
Day 19/21,
Day 38-42
of EBRT,
and Day
68-72 after
EBRT

Voss et al.
(2013).

crosssectional

and scheduled
to receive
EBRT.

expression

during EBRT (p < .05).
After Bonferroni, only
SLC25A23 was
significantly downregulated post-EBRT (p
= .008 - .02).

Controls:
n= 15 age,
gender, and
race matched
controls.

n= 5 HIV
patients with
high fatigue

HIV-related
fatigue

revised 26Item Piper
Fatigue Scale

n=5 HIV
patients with
low fatigue
Controls:
n= 5 healthy
controls

genomic
(mitochondrial and
nuclear) expression
markers of
mitochondrial
dysfunction

CD14+ cells

Eight of the 11
differentially expressed
genes were significantly
associated with fatigue
scores (p = .012 - .0003).
Genes pertaining to
mitochondrial function
include: CHD1L (τ =
-.49) and ALDOB (τ =
-.62), TIMM17B (τ =
.62), GSR (τ = .62),
IMMT (τ = .57), and
SLC25A26 (τ = .62).
2 HIV-associated genes
related to mitochondrial
function, fatty acid
metabolism: ACAD9 (τ
= .20) and PPAR-alpha
(τ = -.44).

CFS= chronic fatigue syndrome; ME= myalgic encephalomyelitis; CDC= Centers for Disease Control and Prevention; DSM III-R = Diagnostic
& Statistical Manual of Mental Disorders 3rd Edition Revised RNA = ribonucleic acid; L/P ratio = lactate/pyruvate ratio; DNA=
deoxyribonucleic acid; mtDNA= mitochondrial DNA; ADLs= activities of daily living; ROS= reactive oxygen species; RNS= reactive nitrogen
species; MDA= malondialdehyde; NO= nitric oxide; SD= superoxide dismutase; GSH= glutathione; RBCs= red blood cells; PCR= polymerase
chain reaction; PBMCs= peripheral blood mononuclear cells; EIF2B4= eukaryotic translation initiation factor 2B, subunit 4δ, tv-1 ; EIF4G1=
eukaryotic translation initiation factor 4γ, 1, tv-5; MRPL23 = mitochondrial ribosomal protein L23; ABCD4= ATP binding cassette, subfamily D
(ALD), member 4, tv-4 ; PEX16=peroxisomal biogenesis factor 16, tv-1; HLA = human leukocyte antigen; CCFP = chronic ciguatera fish
poisoning; GWVs = Gulf War Veterans; PC = prostate cancer; IgM= immunoglobulin subtype M ; IgG= immunoglobulin subtype G ; CoQ10=
Coenzyme Q10; ATP= adenosine triphosphate; TL-IN= transports ATP to cytosol; TL-OUT= transports ADP from cytosol to mitochondria;
aaRNA = amino allyl RNA ; Ox-Phos= oxidative phosphorylation; SOD2= superoxide dismutase 2, mitochondrial; FDX1= ferredoxin 1;
NQO1= nicotinamide adenine dinucleotide phosphate dehydrogenase quinone 1; PFKFB3= 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
3(allosteric enzyme);; PDK4 = pyruvate dehydrogenase kinase, isoenzyme 4 ; GOT1= glutamic-oxaloacetic transaminase 1; AMPD3= adenosine
monophosphate deaminse (isoform E); VLDLR = very low density lipoprotein receptor; FOS= V-fos FBJ murine osteosarcoma viral oncogene
homolog; MYC = v-myc myelocytomatosis viral oncogene homolog; SOX17= SRY-related HMG-box transcription factor;AATF= apoptosis
antagonizing transcription factor; CEBPD = nuclear factor-IL6-beta; ICCME= International Consensus Criteria Myalgic Encephalomyelitis;
ATPmg= whole cell ATP measured by adding excess Mg; ATP end = ATP measured with endogenous Mg only; Nfn= number of factors with
normal; values; MES inh = revised MES using the % ATP inhibited instead of TL IN; MS= multiple sclerosis; EBRT= external beam radiation
therapy; WBCs= white blood cells; SLC25A23 = solute carrier family 25, member 23; HIV= human immunodeficiency virus; CD14 = monocyte;
LDH = lactate dehydrogenase.

CFS patients were the most studied (72% of all articles reviewed). CFS subjects were
phenotyped by clinical diagnosis using the 1988 or 1994 Center for Disease Control (CDC)
diagnostic criteria alone (n=17) or in combination with other developed criteria (n=3), such as
the Australian definition for CFS (n= 1), the British definition for CFS (n=1), and the
International Consensus Criteria for Myalgic Encephalomyelitis (ICCME) (n=1). Two studies
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used other diagnostic guidelines; one used the Oxford Consensus criteria and one group used the
diagnostic criteria established by the Royal Australasian College of Physicians Working Group.
Fatigue was defined either through clinical diagnosis alone or in combination with selfreport questionnaires. Most articles (n=16) quantified fatigue using a variety of questionnaires
such as the Fatigue Severity Scale (n=4), CFS Impairment Index (CFS-II) (n=2), Checklist
Individual Strength (CIS) fatigue subscale (n=2), Sickness Impact Profile (n=2), Chalder Fatigue
Scale (n=1), the Fibromyalgia and the CFS Rating Scale (FF Scale) (n=2), Symptom Checklist
90-R (n=2), CFS Ability Scale (n=2), the revised Piper Fatigue Scale (n=2), Visual Analogue
Scale-fatigue (VAS) (n=1), the Profile of Fatigue (ProF) (n=1), and structured interviews (n=3).
A number of mitochondrial parameters were investigated as potential markers for the
fatigue conditions. In about 70% (n=18) of the studies, mitochondrial biomarkers were obtained
from peripheral blood samples; in the remaining 7 studies, lower extremity skeletal muscle
biopsy specimens were used. Dysfunctions in the mitochondrial structure, mitochondrial
function, mitochondrial energy metabolism, immune/inflammatory response, and genetics were
investigated as potential contributors to fatigue. Studies are grouped into these four areas for
review.
3. 1 Mitochondrial Structure
Four studies investigated the association of fatigue with mitochondrial number, size,
and/or shape. All four studies were cross-sectional in design, included patients with CFS, and
used muscle biopsy specimens to determine the potential mitochondrial markers. One study
quantified fatigue through the use of a self-report questionnaire; whereas, three studies assumed
fatigue through medical diagnosis. In one study about 7% of tibialis anterior (n=69), quadriceps
(n=4), or medial head gastrocnemius (n=1) muscle biopsies from CFS subjects had
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mitochondrial hyperplasia; however, because there were no structural abnormalities noted, the
authors concluded that mitochondrial structural abnormalities were not a feature of CFS
(Edwards, Gibson, Clague, & Helliwell, 1993). Findings were similar in another study in which
no significant mitochondrial structural differences were found in the right leg vastus lateralis
muscle biopsies of CFS patients versus controls (Plioplys & Plioplys, 1995a).
One study investigating the vastus lateralis muscle biopsies of CFS subjects compared to
normal controls found a significantly larger (hypertrophic) mitochondrial size and shape (3-8
times larger), often with noticeable branching of the cristae, termed compartmentalization,
(Behan, More, Downie, & Gow, 1995). In another study of CFS patients with decreased energy
metabolism, the vastus lateralis muscle biopsy specimens, as categorized by observed lactate to
pyruvate production in the biopsy samples, were found to have minor, nonspecific changes to
mitochondrial shape and structure (paracrystalline inclusions and increased numbers of
pleomorphic mitochondria with proliferation of cristae) (Behan, Holt, Kay, & Moonie, 1999).
However, a vastus lateralis muscle specimen from a CFS patient with normal energy metabolism
showed abundant pleomorphic mitochondria, but these structural changes were not observed in
the vastus lateralis muscle specimens from CFS subjects with increased energy metabolism
(Behan et al., 1999).
In summary, three of these four cross-sectional studies investigated the relationship
between fatigue and mitochondrial number, shape, and/or size and found no significant
differences with mitochondrial shape and structure among CFS patients and controls. Only one
study observed significant mitochondrial hypertrophy in the CFS patients compared to healthy
controls using skeletal muscle specimens.
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3.2 Mitochondrial Function
Eleven studies investigated aspects of mitochondrial function; all were cross-sectional in
design. Most studies (n=8) focused on mitochondrial enzymes, while the rest (n=3) focused on
oxidative and/or nitrosative stress. Most studies looked at CFS or ME/CFS patients, while one
study investigated fatigue in SLE patients.
3.2.1 Mitochondrial enzymes.
Four studies measured mitochondrial enzymes using muscle biopsy specimens and the
remaining ones used peripheral blood specimens. Six studies only enrolled CFS patients, one
included ME/CFS patients, and the remaining study enrolled only ME patients. Almost all
participants were enrolled based on their medical diagnosis, except for one study which used a
self-report questionnaire to measure fatigue. In four studies fatigue was further assessed by
structured clinical interviews (n=2) and self-report questionnaires (n=2).
A significant reduction in citrate synthase, succinate reductase, and cytochrome-c oxidase
was observed in the anterior tibialis muscle biopsy samples of CFS patients compared to healthy
controls, which was attributed to the reduction in physical activity commonly present in CFS
subjects (McArdle et al., 1996). A significant reduction in citrate synthase in the right
quadriceps muscle biopsy samples from CFS subjects was also confirmed recently (Smits et al.,
2011). Citrate synthase is located in the mitochondrial matrix and is an essential enzyme in the
citric acid cycle (Tymoczko, Berg, & Stryer, 2010). Succinate reductase (Complex II) and
cytochrome-c oxidase (Complex IV) are two of the four mitochondrial transmembrane enzyme
complexes of the electron transport chain (Tymoczko et al., 2010).
In contrast, one study observed no significant difference with the skeletal muscle biopsies
of partial cytochrome-c oxidase and myoadenylate deaminase (MAD) between CFS patients and
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healthy controls; MAD was more associated with the symptom of myalgia than fatigue (Edwards
et al., 1993). MAD is the muscle-specific subtype of adenosine monophosphate (AMP)
deaminase and is involved in nucleotide metabolism (Tymoczko et al., 2010; Verzijl et al.,
1998). Another study observed no difference in the vastus lateralis muscle biopsy levels of
lactate dehydrogenase and cytochrome-c oxidase activity in CFS patients and controls (Behan et
al., 1999). Lactate dehydrogenase is an enzyme located in the cytoplasm of cells and contributes
to the formation of lactate from pyruvate (Tymoczko et al., 2010).
Four articles examined the levels of Coenzyme Q10 (CoQ10) in fatigued patients with
either ME or CFS compared to healthy controls (Kurup & Kurup, 2003a, 2003b; Maes et al.,
2009a, 2009b). ME and CFS patients had significantly lower plasma levels of CoQ10 compared
to healthy controls (Kurup & Kurup, 2003a, 2003b). Plasma CoQ10 was also observed to be
significantly lower in ME/CFS and depressed patients with CFS compared to controls (Maes et
al., 2009a, 2009b). Significant, inverse relationships were observed with plasma CoQ10 levels
and severity of illness scores of ME/CFS patients, specifically, greater fatigue and autonomic
symptoms were associated with lower levels of CoQ10 (Maes et al., 2009a). However, in
patients with depression there was no correlation observed with severity of illness total or
individual scores and plasma CoQ10 levels (Maes et al., 2009b). The presence of CFS
independently predicted low plasma CoQ10 levels (Maes et al., 2009b; Kurup & Kurup, 2003a,
2003b).
No longitudinal studies investigated the association between mitochondrial enzymes and
fatigue. The cross-sectional studies reviewed reported conflicting associations between
mitochondrial enzymes and fatigue. CoQ10 was the most studied mitochondrial enzyme, where
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reduced plasma levels of CoQ10 were found in the fatigued populations compared to healthy
controls.
3.2.2 Oxidative/Nitrosative stress.
Three cross-sectional studies, two from the same research group, investigated oxidative
and nitrosative stress in CFS and ME patients compared to healthy controls. All three used
peripheral blood specimens for biologic analyses, one study investigated patients with CFS, one
study investigated ME, and one study investigated fatigue in SLE. Two of the studies
complemented medical diagnosis with a structured clinical interview while one study defined
fatigue through the use of self-report questionnaires.
Antioxidants (Glutathione, superoxide dismutase, catalase, GSH peroxidase, and GSH
reductase) were significantly decreased, while ROS and reactive nitrogen species (RNS)
(malondialdehyde [MDA], conjugated dienes, hydroperoxides, and nitric oxide) were
significantly increased in the plasma/serum samples of CFS patients compared to healthy
controls (Kurup & Kurup, 2003a). Similar results were observed in subjects with ME (Kurup &
Kurup, 2003b). It is hypothesized that the aforementioned disruption in the oxidative stress
pathway is the downstream result of an imbalance in intracellular calcium and magnesium,
which results in high intracellular calcium and low intracellular magnesium (Kurup & Kurup,
2003a, 2003b).
Another study investigated the association between F 2 -isoprostance levels and fatigue in
patients with SLE. They observed that fatigued SLE patients had higher levels of F 2 isoprostane than non-fatigued SLE patients (Segal et al., 2012). A positive correlation between
F 2 -isoprostane and fatigue was observed in SLE patients and it was observed that F 2 -isoprostane
predicts higher FSS scores in SLE patients. F 2 -isoprostane is currently acknowledged as the
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most reliable measure of in vivo oxidative stress (Segal, 2012). The results from this study
provide further evidence of an association between oxidative stress and the development of
fatigue.
3.3 Mitochondrial Energy Metabolism
Ten studies investigated aspects of mitochondrial energy metabolism; all were crosssectional in design. Most studies (n=6) focused on fatty acid metabolism, while the rest (n=4)
focused on ATP production. Most studies looked at CFS or ME/CFS patients, while one study
investigated fatigue in MS patients.
3.3.1 ATP production.
Four cross-sectional studies investigated mitochondrial energy metabolism as a potential
marker in fatiguing conditions. Mitochondrial energy metabolism was assessed from muscle
biopsies in two of the studies and from peripheral blood in the remaining studies. Two studies
only enrolled CFS patients, while the remaining two studies included both ME and CFS patients.
The mitochondrial energy metabolism was measured using the ATP profile test in two
studies (Myhill, Booth, & McLaren-Howard, 2009; Booth, Myhill, & McLaren-Howard, 2012).
The ATP profile tests measures three parameters of mitochondrial function in neutrophils
extracted from peripheral blood, (1) ATP concentration (how much ATP is present) and ATP
ratio (what fraction of ATP is available for energy supply), (2) the efficiency of oxidative
phosphorylation (ADP to ATP recycling efficiency), and (3) TL OUT (ADP out of cytosol into
mitochondria) and TL IN (ATP from mitochondria into the cytosol). A Mitochondrial Energy
Score (MES) was calculated by multiplying all five factors (ATP, ATP ratio, Ox Phos, TL OUT,
TL IN, TL OUT x TL IN). One of the two studies that used this ATP Profile test observed that
the percentage of participants with normal values of mitochondrial function increased as fatigue
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symptoms decreased (Myhill et al., 2009). In addition, the MES was positively correlated with
scores on the CFS Ability scale (Myhill et al., 2009) indicating that greater mitochondrial
efficiency was associated with higher levels of activity and function in those with CFS/ME.
A second study by the same group confirmed the presence of mitochondrial dysfunction
in patients with ME/CFS by observing partial blockage of the ADP-ATP translocator protein,
adenosine nucleotide translocase (TL) (Booth et al., 2012). The TL protein functions to transfer
ATP out of the mitochondria into the cell cytoplasm as well as transferring ADP from the cell
cytoplasm into the mitochondria to generate more ATP (Booth, 2012). Cells can compensate for
some of the dysfunction in ATP production through two alternative pathways: by increased
glyocolysis and the use of adenlyate kinase pathway of ATP formation (Booth et al., 2012).
Therefore, partial blockage of the TL protein can lead to impaired energy production.
Another study measured two aspects of energy metabolism in the vastus lateralis muscle
biopsy samples: aerobic respiration and respiratory chain function, which showed no difference
between CFS patients and healthy controls for either parameter (Behan et al., 1999). In addition,
there were no differences in ATP production rate or respiratory chain complex activity found in
the right quadriceps muscle biopsy samples of CFS patients compared to healthy controls (Smits
et al., 2011). Although ME/CFS patients had impaired energy production as determined by the
ATP profile test, no differences in either aerobic respiration or respiratory chain complex activity
were found in CFS patients compared to healthy controls.
3.3.2 Fatty acid metabolism.
Six cross-sectional articles investigated carnitine levels in fatiguing conditions. Five
studies included CFS patients and one study included MS patients. Four studies used peripheral
blood specimens for biologic analyses and two studies used muscle biopsies. Four studies
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complimented medical diagnosis with self-report questionnaires, while two studies assumed
fatigue through medical diagnosis.
Acylcarnitine serum levels were significantly lower in CFS patients compared to healthy
controls; however, free L-carnitine serum levels were not significantly different between the two
groups (Kuratsune et al., 1994). Another study observed significantly lower serum levels of total
and free carnitine in CFS patients of both genders when compared to healthy controls, as well as
lower serum levels of acylcarnitine in CFS patients compared to controls, using historical data
(Plioplys & Plioplys, 1995b). However, no difference between total, free, and acylcarnitine
serum levels were found in a more recent study of CFS patients versus healthy controls
(Soetekouw et al., 2000), as well as in patients with MS (with and without fatigue) compared to
healthy controls (Fukazawa, Sasaki, Kikuchi, Hamada, & Tashiro, 1996). Another study also
showed no significant difference in L-carnitine, total carnitine, or total acylcarnitine plasma
levels between CFS patients and healthy controls; however, when individual acylcarnitine
subtypes were investigated in the CFS sample, 6 acylcarnitine subtypes (C8:1, C14, C16:1, C18,
C18:1, and C18:2) were significantly lower, while 2 acylcarnitine subtypes (C12DC and C18:1OH) were significantly higher in plasma of CFS participants compared to the matched controls
(Reuter & Evans, 2011).
Higher acylcarnitine serum levels were inversely correlated with the Chronic Fatigue
Syndrome Impairment Index (CFS-II) mental index score and CFS-II total score (Plioplys &
Plioplys, 1995a). Lower serum acylcarnitine was associated with worse activity levels and
symptom presentation, but these relationships were not observed with free L-carnitine serum
levels (Kuratsune et al., 1994). A later study, however, showed that higher free carnitine serum
levels were significantly associated with better physical abilities, and higher free and total
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carnitine serum levels were significantly associated with lower fatigue severity (Plioplys &
Plioplys, 1995b).
4. Immune Response
Four studies investigated dysfunctional immune responses to mitochondria in various
fatiguing conditions. Three of these studies were cross-sectional and one study used repeated
measures. Three studies only enrolled CFS patients and one study included fatigued patients with
various diagnoses. Three studies used peripheral blood specimens for biologic analyses, while
one study used muscle biopsies. In one study clinical diagnosis was complemented with selfreport questionnaires and interview assessments, while three studies assumed fatigue through
medical diagnosis.
Two studies from the same research group investigated autoimmune responses to acute
phase phospholipids in patients with fatiguing illnesses (Hokama et al., 2008, 2009). CFS
subjects had serum lipid fractions that resembled those commonly found in patients poisoned
with ciguatoxin, a marine toxin (Hokama et al., 2008). Sera from patients with CFS, chronic
ciguartera fish poisoning (CCFP), gulf war veterans (GWV), and prostate cancer patients
contained antibodies to cardiolipin (aCL), a phospholipid of the mitochondrial membrane
(Hokama et al., 2008). Further study found that 95% of CFS patients had anticardiolipin
antibody (ACA) of the IgM subtype, 10% showed an IgG response, 2.5% had an IgA response; 4
patients were positive for IgG and IgM, and one patient was positive for all three antibody
subtypes (Hokama et al., 2009).
Two studies investigated the role of enteroviral infection with the onset of CFS (McArdle
et al., 1996; Vernon et al., 2006). One study examined anterior tibialis muscle biopsy specimens
for the presence of enteroviral RNA. However, they failed to detect the presence of a persistent
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enteroviral infection in patients with CFS (McArdle et al., 1996). Another study observed 23
differentially expressed genes from peripheral blood samples of patients with persistent postEpstein-Barr (EBV) fatigue compared to controls (those who recovered without persistent
fatigue) in the early phase (0-3 months) of infection. Of the 23 differentially expressed genes, 8
were found in subjects with persistent fatigue post-EBV and were involved in binding and
metabolism ontologies (Vernon et al., 2006). When exploring both early and late (>6 months)
phases of infection, 24 genes were differentially expressed between cases and controls. Half of
the 24 differentially expressed genes were associated with mitochondrial functions such as fatty
acid oxidation (CRAT, carnitine acetyltransferase; APOA2, apolipoprotein A-II), apoptosis
(BTG1, B-cell translocation gene 1; FOLR1, folate receptor 1; CTRL, chymotrypsin-like), DNA
repair, and mitochondrial membrane (COX8A, cytochrome c oxidase subunit VIII; COX11,
cytochrome c oxidase assembly protein; KCNA10, potassium voltage-gated channel; MGP,
matrix G1a protein; ATP5L, ATP synthase) (Vernon et al., 2006).
In the four studies reviewed an autoimmune response was found as evidenced by the
presence of mitochondrial phospholipids in the sera of CFS patients. Although there was no
evidence of persistent enteroviral infection found in muscle biopsies of CFS patients, differential
expression of genes associated with mitochondrial function was noted in patients post EBV
infection. Comparing the results among these studies is challenging. Only one research group
investigated autoimmune responses to acute phase phospholipids, publishing two different
studies. Both of the studies investigating post-infective fatigue investigated different viral
infections (enterovirus vs. EBV) and the two studies employed different study designs, crosssectional (McArdle et al., 1996) and repeated measures (Vernon et al., 2006).
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5. Genetics
Five articles explored the association between gene expression profiles in fatigue
conditions versus controls. Three studies were cross-sectional and two studies used repeated
measures designs. Three studies only included CFS patients, one study included men with
prostate cancer, and one study included patients with Human Immunodeficiency Virus (HIV).
Three studies used peripheral blood specimens for genomic analyses, while two studies used
muscle biopsies. One study complemented clinical diagnosis with self-report questionnaires, two
studies used self-report questionnaires alone to measure fatigue, and two assumed fatigue
through medical diagnosis.
The first genomic study found no significant differences between CFS patients and
healthy controls in the total volume of mitochondrial DNA present, two mtDNA rearrangements,
and the presence of one point mutation (Behan et al., 1999). A real-time PCR (qPCR) study
found 11 mitochondrial function-related genes to be differentially expressed during radiation
therapy for prostate cancer and 8 of the 11 genes were significantly associated with fatigue
intensification during radiation therapy (Hsiao et al., 2013). These 8 genes are involved in
mitochondrial apoptosis and signaling, mitochondrial membrane polarity and potential,
mitochondrial morphology and fission/fusion, and mitochondrial and small molecule transport
(Hsiao et al., 2013).
One microarray analysis found 35 differentially expressed genes in the peripheral blood
mononuclear cells (PBMCs) from CFS patients, where 3 up-regulated genes had activities
specific to mitochondrial function: EIF2B4 (eukaryotic translation initiation factor 2B, subunit
4δ, tv-1), EIF4G1 (eukaryotic translation initiation factor, 4γ, 1, tv-5), and MRPL23
(mitochondrial ribosomal protein L23) (Kaushik et al., 2005). Another microarray study found
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47 differentially expressed genes (2 up-regulated and 38 down-regulated in both genders; 7 upregulated in females, yet down-regulated in males) from vastus lateralis muscle biopsies of CSF
patients compared to healthy controls. The down-regulated genes were associated with
impairment of antioxidant mechanisms, aerobic energy production, and metabolism (Pietrangelo
et al., 2009). Another study investigated gene networks in CD14+ cells from HIV-infected
patients who reported high fatigue, versus those who reported low fatigue or healthy controls,
where 6 mitochondrial-related genes (CHD1L and ALDOB genes were negatively associated
with fatigue; TIMM17B, GSR, IMMT, and SLC25A26 were positively associated with fatigue)
are implicated in protein translocation into the mitochondrial matrix, cristae morphology, ATPbinding and protein binding, metabolism, oxidation and reduction processes, and energy
production were identified (Voss et al., 2013).
Five articles explored the association between gene expression profiles in fatiguing
conditions versus controls. Common mitochondria-specific functional pathways were reported
from the results of the gene expression studies included in review, to include pathways related to
metabolism, energy production, protein transport, mitochondrial morphology, central nervous
system dysfunction and post-viral infection. The pathways identified in these studies were
similar across three different patient populations and supported areas of dysfunction identified in
the previous sections.
6. Discussion
The purpose of this systematic review was to examine markers of mitochondrial function
that have evidence of an association with fatigue in order to identify areas needed for further
research. This review included studies focusing on markers of mitochondrial function in relation
to fatigue. Dysfunctions in the mitochondrial structure, mitochondrial function (mitochondrial
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enzymes and oxidative/nitrosative stress), mitochondrial energy metabolism (ATP production
and fatty acid metabolism), immune response, and genetics were investigated as potential
contributors to fatigue.
Carnitine was the most investigated mitochondrial function marker reported in this
review (n=6). Dysfunctional carnitine levels were reported in all six studies that investigated the
biomarker; however, the specifics of the dysfunction varied among the studies. Genetic profiles
were the second most studied mitochondrial parameter. Even though different genes were
reported across the studies, common pathways (metabolism, energy production, protein
transport, mitochondrial morphology, central nervous system dysfunction, and post-viral
infection) were identified among the articles. The most commonly investigated mitochondrial
enzyme was CoQ10. It was the only mitochondrial biomarker found to have a consistent
association with fatigue identified in this review (Kurup & Kurup, 2003a, 2003b; Maes et al.,
2009a, 2009b). CoQ10 is an essential enzyme in the electron transport chain, responsible for
shuttling electrons and protons (Tymoczko et al., 2010). Further investigation is needed to
understand the role of CoQ10 in fatigue.
CoQ10 deficiency can be either primary or secondary in nature. Primary deficiency
stems from dysfunction with the genes coding for the synthesis of CoQ10, whereas secondary
deficiency results from anything that is not primary in nature (Horvath, 2012; Littarru & Tiano,
2010); Potgeiter, Pretorius, and Pepper, 2013). CoQ10 is endogenously produced and therefore,
dietary intake has minimal influence on the CoQ10 concentration in the body. However, if
CoQ10 is found to be depleted, especially with primary deficiency, supplementation is a
therapeutic option (Potgeiter, Pretorius, and Pepper, 2013). In clinical practice, vitamins such as
riboflavin B2, niacin B3, vitamin E and other mitochondrial cofactors including levo-carnitine,
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lipoic acid, acetyl-l-carnitine are used as supplemental treatment for mitochondrial disorders in
order to either enhance ETC enzyme activity or antioxidant defenses (Cohen, 2000). The
efficacy of these vitamins and mitochondrial cofactors as treatments for mitochondrial disorders
remain controversial (Cohen, 2000).
CoQ10 has been shown to have clinical benefits attributed to its antioxidant properties
and its role in cellular bioenergetics (Littarru & Tiano, 2010); hence, it is being used as a
therapeutic option for a number of mitochondria-related clinical conditions including those with
cardiovascular disease, reproductive issues, and neurodegenerative diseases (Littarru & Tiano,
2010). In this review, there are only two research teams that investigated the relationship
between CoQ10 and fatigue. More clinical studies are needed to confirm the role of vitamins
and mitochondrial cofactors in alleviating fatigue symptoms (Horvath, 2012; Potgeiter, Pretorius,
and Pepper, 2013).
Based on the findings of this review, alterations in energy metabolism may contribute to
fatigue. Support for this conclusion was evident from dysfunctions reported with both oxidative
phosphorylation and ATP production and recycling. Impaired oxidative phosphorylation was
noted through reduced citrate synthase activity, reduced levels of succinate reductase (Complex
I), cytochrome-c oxidase (Complex IV), and CoQ10 (electron shuttle from Complex I and II to
Complex III), as well as evidenced through disrupted oxidative stress (decreased levels of
antioxidants and increased levels of ROS and F 2 -isoprostance) (McArdle et al., 1996; Kurup &
Kurup, 2003a, 2003b; Maes et al., 2009a, 2009b; Segal et al., 2012; Smits et al., 2011). ATP
concentration, recycling, and the efficiency of oxidative phosphorylation were found to be
disrupted through the ATP Profile Test (Myhill et al., 2009; Booth et al., 2012). Fatty acid
metabolism was also impaired as evidenced by abnormal carnitine levels (Kuratsune et al., 1994;
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Plioplys & Plioplys, 1995a, 1995b; Reuter & Evans, 2011). Genetic investigations found
abnormal gene transcription pathways related to metabolism, energy production, protein
transport (Hsiao et al., 2013; Kaushik et al., 2005; Pietrangelo et al., 2009; Voss et al., 2013).
These genetic pathways support and the areas of dysfunction found in the aforementioned
studies.
The limitations identified in this review are: 83% of the studies were cross-sectional, 79%
of the studies enrolled only CFS patients, and there were inconsistent associations found between
mitochondrial biomarkers and fatigue. Future studies utilizing longitudinal designs need to be
conducted to establish associations between mitochondrial dysfunction and fatigue development.
Additionally, if mitochondrial dysfunction and fatigue are observed, longitudinal studies can
provide more evidence about the characteristics of the association.
The inclusion of diverse patient populations in future studies would provide evidence
regarding common mitochondrial mechanisms as an etiology for fatigue. The predominant
patient population included in the reviewed studies was CFS. Knowledge gained from studies of
the CFS population needs to be translated to other fatigued populations, such as those with
cancer or other chronic diseases. Understanding the biological mechanisms underlying fatigue
development is important to enhance clinical evaluation and treatment.
Furthermore, fatigue was defined differently among the reviewed studies and different
diagnostic criteria and self-report instruments were used. This variability limited the ability to
compare findings across studies. Furthermore, the self-report questionnaires included in the
reviewed studies are valid measures of fatigue, but not necessarily for the populations included
in the studies, namely CFS. Future research needs to work towards establishing a global
agreement on the clinical definition of fatigue. Once a clinical definition of fatigue is established,
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research will need to focus on developing a valid and reliable tool for measurement of fatigue in
the clinical setting. Until a global definition is developed, researchers need to ensure that the
existing fatigue tools are validated in their clinical populations of interest.
The literature review identified some potential relationships between mitochondrial
dysfunction and fatigue; however, the findings were limited to predominantly one patient
population, were from mostly cross-sectional studies, and results were confounded by the use of
multiple definitions of fatigue. These limitations culminated in inconsistent findings across
studies. Therefore, the results from the review suggest further investigation to address the gaps in
the current literature. Once the underlying mechanisms of fatigue are better understood,
individualized and tailored therapies can be developed to improve quality of life of patients.
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Chapter Three

Prostate cancer (PC) is the most common type of cancer in men, outside of skin cancer,
and the second leading cause of cancer death among American men (American Cancer Society
[ACS], 2014). It is estimated that in 2014, there will be 2.5 million men in the United States with
PC, and 233,000 of them will be newly diagnosed. These statistics indicate that PC is a condition
that affects a significant number of men; about 1 in 7 men will be diagnosed during their
lifetime. Fortunately, advances in diagnosis and treatment have greatly improved the prognosis
and survival of men with PC (ACS, 2014).
Treatment for PC depends on patient and disease characteristics. If the cancer is localized
or has progressed into the nearby tissue, then various forms of radiation therapy (RT) may be
implemented (ACS, 2014). External beam radiation therapy (EBRT), for example, can be an
effective treatment option, but it can result in numerous side effects including urinary, bowel,
and sexual dysfunctions, as well as fatigue, which can greatly impair the individual’s healthrelated quality of life (HRQOL) (Budäus et al., 2012). A systematic review comparing fatigue
prevalence among different treatment modes for PC found that chronic fatigue or clinicallysignificant fatigue, as determined through scores on various self-report assessments, was present
in 13-22% of men who had radical prostatectomy, and a similar rate was found in patients on
active surveillance (Langston, Armes, Levy, Tidey, & Ream, 2013). However, it was observed
that 71% of men reported clinically significant fatigue while receiving radiation therapy.
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Additionally, 24-33% of men experienced persistent fatigue more than one year post-RT
(Langston et al., 2013).
Fatigue related to RT is a type of cancer-related fatigue (CRF). CRF is one of the most
commonly reported side effects of cancer and its treatment, affecting about 80% of people
receiving chemotherapy or RT (Hofman, Ryan, Figueroa-Moseley, Jean-Pierre, & Morrow,
2007; National Comprehensive Cancer Network [NCCN], 2012; Piper & Cella, 2010). People
with cancer often characterize CRF as a lack of energy, weakness, muscle heaviness, inability to
recover from physical activity in a timely manner, the need for exaggerated effort to complete a
task, or once the task is complete, the need for greater rest periods (Cheville, 2009; Hofman, et
al., 2007; Mitchell & Berger, 2011). Not only is CRF one of the most prevalent symptoms, it is
also reported to be one of the most distressing, often negatively affecting multiple HRQOL
domains (Barsevick, Frost, Zwinderman, Hall, & Halyard, 2010; Ryan, et al., 2007; Tazi &
Errihani, 2011). CRF is poorly understood and lacks a clear, single, clinical definition or
etiology. This makes it a challenging symptom for healthcare providers to diagnose, resulting in
increased symptom burden, and decreased HRQOL.
The biological basis for fatigue in individuals with cancer is an area of great research
interest. Many different biological mechanisms have been theorized to play a role in the etiology
of CRF, such as proinflammatory cytokines, serotonin dysregulation, and hypothalamicpituitary-adrenal axis dysfunction (Wang, 2008). An alternative, plausible biological mechanism
for fatigue is mitochondrial dysfunction. Self-reported descriptions of reduced energy and
muscle weakness lend support for a possible relationship of CRF to mitochondrial dysfunction in
that these symptoms are similar to those that might be present with mitochondrial disease (such
as exercise intolerance and weakness, among other skeletal muscle and energy or metabolic
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manifestations) (Haas et al., 2007). Therefore, mitochondrial dysfunction is a plausible
mechanism of CRF.
Mitochondria have an essential role in energy production through the process of oxidative
phosphorylation whereby nutrients are converted into adenosine triphosphate (ATP), which
powers many of the cells’ activities. In addition to energy production, mitochondria have been
implicated in various physiologic processes including the production of reactive oxygen species
(ROS), pyrimidine and lipid biosynthesis, regulation of cellular levels of substrates (amino acids,
metabolites, enzyme cofactors), apoptosis, metal (Fe-S cluster and heme) metabolism, calcium
homeostasis and flux, neurotransmitter synthesis, heat production, and insulin secretion (Duchen,
2004; Nunnari & Suomalainen, 2012; Pieczenik & Neustadt, 2007). Therefore, damage to
mitochondria can have widespread health outcomes (Duchen, 2004). Mitochondria are becoming
increasingly recognized as major contributors to human health and disease because of their
widespread influences (Cohen & Gold, 2001).
Radiation therapy has been observed to cause mitochondrial dysfunction through two
primary insults. First, radiation can induce a decline in mitochondrial electron transport chain
(ETC) enzyme function (Yoshida, Goto, Kawakatsu, Urata, & Li, 2012). Secondly, with the
decline in ETC function, there is a resulting increase in the production of ROS (Yoshida et al.,
2012). ROS production under normal conditions is beneficial for cellular signaling; however,
during exposure to radiation, ROS production increases to toxic levels resulting in damage to
mitochondrial and nuclear DNA, thereby disrupting normal cell metabolic and physiologic
activities (Azzam, Jay-Gerin, & Pain, 2012). While mitochondrial dysfunction has been
suggested as a possible mechanism underlying CRF (Wang, 2008), only one reported study has
investigated the potential role of mitochondrial dysfunction in CRF (Hsiao, Wang, Kaushal, &
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Saligan, 2013). The investigators examined changes in fatigue scores (measured by the revised
Piper Fatigue Scale) and mitochondria-related gene expression (measured from RNA in
peripheral blood) at seven time points (baseline, day 1, day 7, day 14, treatment midpoint,
treatment completion, and 30-days post treatment) during EBRT in men with nonmetastatic
prostate cancer. The investigators observed that differential expression of genes related to
mitochondrial metabolism, energy production, and protein transport were associated with selfreported fatigue in their participants (Hsiao et al., 2013).
Mechanisms underlying mitochondria-related disease states have predominantly focused
on DNA damage and ROS generation (Cohen & Gold, 2001; Pieczenik & Neustadt, 2007).
Mitochondrial dysfunction can be categorized as primary (inherent) or secondary (acquired
dysfunction) (Cohen & Gold, 2001; Read & Calnan, 2000). Primary dysfunction results from
mitochondrial DNA (mtDNA) mutations inherited from mothers, who are the sole contributors
of mitochondria to their offspring (Cohen & Gold, 2001). Mitochondrial DNA has a much higher
mutation rate than nuclear DNA because it lacks protective histones (Read & Calnan, 2000), is
readily exposed to damage from ROS production (Alexander et al., 2010; Pieczenik & Neustadt,
2007; Reynolds et al., 2007), and lacks certain DNA repair mechanisms (Cohen & Gold, 2001).
Secondary mitochondrial dysfunction results from the influence of external mechanisms such as
environmental or pharmacologic toxins that can damage the mtDNA (Cohen & Gold, 2001).
Mitochondria can protect themselves from the accumulation of damage through the processes of
fission and fusion (Chan, 2006; Nunnari & Suomalainen, 2012; Youle & van der Bliek, 2012);
however, if these mechanisms are altered, mitochondrial dysfunction can contribute to diseases
such as cancer, diabetes, Alzheimer’s Disease, Parkinson’s Disease, Fibromyalgia Syndrome,
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and serious mental disorders such as schizophrenia and bipolar disease (Blackstone & Chang,
2011; Duchen, 2004; Pieczenik & Neustadt, 2007; Reynolds et al., 2007).
Mitochondrial research has predominantly focused on the role of mitochondrial
dysfunction in disease pathology (Chan, 2006; Seo et al., 2010). However, there has been some
work associating mitochondrial dysfunction with the development of distressing symptoms such
as fatigue, neuropathic pain, weakness, and depression in addition to disease states (Pieczenik &
Neustadt, 2007). Abnormal (swollen and vacuolated) mitochondria have been observed to have a
relationship with chemotherapy-induced neuropathy in the absence of evidence of nerve fiber
damage or dysfunction (Flatters & Bennett, 2006). Patients with depression have also been
observed to have alterations in metabolism, specifically with mitochondrial ETC enzymes
(Rezin, Amboni, Zugno, Quevedo, & Streck, 2009). More research is needed to understand the
role of mitochondrial dysfunction in symptom onset or exacerbation.
Given the paucity of research in this area, the current study was designed to expand
knowledge of the relationship of mitochondrial dysfunction to fatigue and HRQOL at baseline
and at completion of EBRT among men with nonmetastatic (NM)-PC. This study was a
secondary analysis of existing data from a National Institutes of Health (NIH ) Institutional
Review Board approved study titled Relationship between Mitochondrial Dysfunction and
Fatigue in Cancer Patients Following External Beam Radiation Therapy (#10-NR-0128).
Specific aims of the secondary study were to: (1) describe levels of biomarkers of mitochondrial
function, fatigue, and HRQOL before and at the completion of EBRT, (2) examine relationships
over time in levels of biomarkers of mitochondrial function, fatigue, and HRQOL, and (3)
compare levels of biomarkers of mitochondrial function in men with non-clinically significant
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fatigue (low fatigue) to those with clinically significant fatigue (high fatigue) from baseline to
completion of EBRT.
Conceptual Framework
Biobehavioral research encompasses interactions of the physiological, psychological,
and social components of health (Grady, 2006). For the purposes of this research, HRQOL of
men with NM-PC was conceptualized within a biobehavioral framework with individual,
treatment, and disease-related factors, biological factors, behavioral manifestations, and HRQOL
components (Figure 1).
Figure 1. Biobehavioral Research Model

Individual and disease-related factors. Individual factors were empirically defined as
demographic data and comorbidities. Disease-related factors were defined as tumor
characteristics (Gleason scores), tumor-related laboratory markers (prostate specific antigen
[PSA]), and tumor burden (tumor-stage [t-stage]). Gleason scores indicate the extent of tumor
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differentiation (range = 1 [well differentiated] to 5 [lack of differentiation]) (Epstein, Allsbrook,
Amin, Egevad, & the ISUP Grading Committee, 2005). Higher Gleason scores indicate less
prostate tissue differentiation, suggesting that the disease is more likely to spread (Epstein et al.,
2005). PSA levels are used in the routine screening of men for detection of prostate cancer
(Pater, Hart, Blonigen, Lindsell, & Barrett, 2012) and as a surveillance marker for disease
progression or recurrence. T-staging is used to grade the severity of prostate cancer, ranging
from stage 1a (early-stage) to stage IVb (metastatic cancer) (Cheng, Montironi, Bostwick,
Lopez-Beltran, & Berney, 2012).
EBRT. Radiation-related factors included radiation dose and length of treatment.
EBRT treatment can result in untoward side effects that could impact patient HRQOL (ACS,
2014).
Biological factors. Biological factors included biomarkers of mitochondrial function
(complex I-V; SOD2) that may result from the disease and/or its treatment. Despite sharing
similar disease profiles and treatment regimens, men with NM-PC can exhibit great variance in
their symptom severity. The underlying mechanisms behind the symptoms and severity of
symptoms are not clear. Mitochondrial dysfunction is one plausible mechanism for the presence
of symptoms such as CRF.
Behavioral manifestation. The behavioral manifestation for this study was fatigue, a
highly prevalent symptom in cancer patients (Hofman et al., 2007; NCCN, 2012; Piper & Cella,
2010). While fatigue has been associated with mitochondrial dysfunction in various clinical
populations (Pieczenik & Neustadt, 2007), these associations have not yet been examined in men
with NM-PC.
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Health-related quality of life. As more treatment options are emerging for PC, HRQOL
is becoming an increasingly important factor in the treatment decision-making process (Torvinen
et al., 2013). Even though it is a crucial concept in health research, HRQOL has been difficult to
define because of its complexity, with meaning imparted by the values of the individual.
However, accurately assessing HRQOL is important for addressing the individual’s well-being
during and after the treatment process.
Methods
This paper reports a secondary analysis of a descriptive, longitudinal study Relationship
between Mitochondrial Dysfunction and Fatigue in Cancer Patients Following External Beam
Radiation Therapy that was approved by the NIH Institutional Review Board (#10-NR-0128).
Men were enrolled if they: (a) had NM-PC, (b) were scheduled to receive EBRT, and (c) were 18
years of age or older. Patients were excluded if they: (a) had any inflammatory or infectious
condition such as rheumatoid arthritis, lupus, or cirrhosis; an infectious disease such as HIV,
tuberculosis, or hepatitis; (b) had other types of cancer; (c) had a major psychiatric disorder or
alcohol or drug abuse within the past 5 years; (d) were receiving or scheduled to receive
chemotherapy; or (e) were taking steroids, non-steroidal anti-inflammatories, or tranquilizers. All
study participants were seen in the outpatient clinics of the Radiation Oncology Department of
the National Cancer Institute (NCI) at NIH, Bethesda, MD from August 2010 to August 2012.
Study time points. Data for this study were collected at two time points: baseline (before
EBRT) and on the last day (completion) of EBRT. Study variables were measured using
demographic, questionnaire, and biologic data sources.
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Demographic data. Demographic data were obtained by reviewing medical records to
obtain age, race, socioeconomic status, and disease-related factors including tumor
characteristics and tumor-related laboratory markers.
Questionnaire data. CRF is a complex symptom because of its multidimensional nature
(Given, 2008). Therefore, two previously validated self-report fatigue questionnaires were used
to quantify various dimensions of participants’ fatigue.
The revised Piper Fatigue Scale (rPFS). This is a 22-item paper/pencil questionnaire that
measures multiple dimensions of fatigue: behavioral/severity (6 items), sensory (5 items),
cognitive/mood (6 items), and affective meaning (5 items) using a 0 to 10 intensity rating scale
(0 = none; 10 = worst intensity). Psychometric properties of the rPFS from previous studies have
included excellent reliability and validity estimates when used in cancer patients; internal
consistency ranged from 0.83 to 0.97 for the total instrument and its subscales (Borneman et al.,
2011).
The Functional Assessment of Cancer Therapy– Fatigue subscale (FACT-F). This is a
validated 13-item questionnaire exploring fatigue symptoms in various populations, including
cancer patients and healthy participants. This questionnaire has shown good test-retest reliability
(r = 0.90), and internal consistency (α = 0.93 and 0.95) on initial and test-retest administration,
suggesting that it can be administered as an independent, unidimensional measure of fatigue
(Yellen, Cella, Webster, Blendowski, & Kaplan, 1997). The FACT-F can also be used to
measure minimally important changes that may be clinically relevant. A greater than or equal to
3-point decrease in the FACT-F score is considered to be the threshold denoting a minimallyimportant change that may be clinically relevant (Cella, Eton, Lai, Peterman, & Merkel, 2002).

47

HRQOL was measured using the FACT-Prostate (FACT-P) questionnaire. This
questionnaire assesses HRQOL in five different domains: physical well-being (7 items),
social/family well-being (7 items), emotional well-being (6 items), functional well-being (7
items), and the PC-specific assessment of functional status (12 items). The instrument has been
validated for use in men with PC (across two samples, internal consistency α = 0.87 to 0.89)
(Esper et al., 1997; Cella, Nichol, Eton, Nelson, & Mulani, 2009).
Mitochondrial measures. Peripheral blood collected at both study time points was used to
obtain protein markers of mitochondrial function.
Cell lysate collection. Peripheral whole blood samples collected using
ethylenediamineteraacidic (EDTA) tubes were centrifuged immediately after collection at 3,000
rpm in 4˚C for 10 minutes. After the plasma was extracted from the tube, the remaining cell
sample was divided into 500 µl aliquots and stored in -80ºC freezers until batch analysis. The
cells from the whole blood samples were lysed with a cell extraction buffer (10mM Tris, pH 7.4,
100mM NaCl, 1mM EDTA, 1% Trition X-100, 10% Glycerol, and 0.1% SDS). A protease
inhibitor was added to the buffer to prevent the degradation of enzymes. Protein content was
quantified using the PierceTM BCATM Protein Assay (Thermo Fisher ScientificTM, Rockford, IL)
per manufacturer’s protocol. After protein quantification, the cell lysate samples were diluted
with incubation buffer per assay protocol and stored at -20˚C overnight.
Serum preparation. Peripheral whole blood collected using serum-separating tubes (SST)
was centrifuged immediately after collection at 3,000 rpm and 4˚C for 10 minutes, then the
serum was divided into 250 µl aliquots that were stored in -80ºC freezers until batch analysis.
Two areas of mitochondrial function were investigated in this study: (a) energy
metabolism and (b) oxidative stress.
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Energy metabolism: Mitochondrial electron transport chain. The respiratory chain is
comprised of five enzyme complexes, respiratory complexes I-V (Azzam, Jay-Gerin, & Pain,
2012). Dysfunction in any complex could interrupt the transfer of electrons, thereby disrupting
efficient and effective energy metabolism. The Human Profiling ELISA kits (Abcam®,
Cambridge, MA) were used for the quantitative detection of the mitochondrial respiratory
enzyme complexes (complexes I-V; 1 kit for each complex) from cell lysates.
Oxidative stress: Antioxidants. Manganese superoxide dismutase (MnSOD) provides the
first line of defense against ROS in the mitochondria, countering oxidative stress (Lustgarten et
al., 2011). Serum MnSOD levels were assessed by the MnSOD ELISA kit (Abcam®, Cambridge,
MA).
Statistical Analysis
Descriptive statistics were used to illustrate the demographic characteristics of
participants. If variables were normally distributed, means and standard deviations were reported
versus medians and ranges data that was not normally distributed. Medians and ranges were
calculated for fatigue questionnaires, and means and standard deviations were calculated for
HRQOL questionnaires. Mitochondrial enzymes were described with medians and ranges.
Nonparametric Wilcoxon matched-pairs rank-sum tests were used to analyze changes in levels of
fatigue between baseline and completion of EBRT. A paired t-test was used to analyze changes
in levels of HRQOL between baseline and completion of EBRT. Mitochondrial data were logtransformed and paired t-tests were used to analyze changes in levels of biomarkers of
mitochondrial function over time. Estimated correlations of mitochondrial biomarkers, fatigue
(as assessed by rPFS and FACT-F scores), and HRQOL were calculated using Pearson’s
product-moment correlation coefficients if both variables were normally distributed and
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Spearman’s rank correlation coefficients if one or more of the variables was not normally
distributed. Participants in this study were grouped into clinically significant (high) and nonclinically significant (low) fatigue groups based on changes in FACT-F scores from baseline to
completion of EBRT. High fatigue groups had a decrease of 3 or more points in FACT-F scores,
while those who had less than a 3-point decrease in FACT-F scores were categorized in the low
fatigue group.
Power analysis. The primary purpose of this dissertation study is to explore the
relationship between mitochondrial function and fatigue intensification during EBRT in men
diagnosed with NM-PC who completed an NINR protocol (# 10-NR-0128) at the NIH, Bethesda,
MD. Minor diagnostic criteria for primary respiratory chain (RC) disorders in adults include a
30%–40% activity (effect size 0.30 - 0.40) of any RC complex, as observed in fibroblasts or
lymphoblasts (Bernier, 2002). An n = 25 has an 80% power to show a difference in levels of
mitochondrial markers before and after EBRT at an effect size of 0.58 with an alpha of 0.05. A
secondary aim of this study is to examine relationships over time with changes in levels of
fatigue, mitochondrial function, and HR-QOL. A study by Hsiao et al. (2013) found significant
correlations between fatigue scores and differential expression of mitochondrial genes during
EBRT with an n = 15. Therefore, the sample size n = 25 will be sufficient to address a secondary
aim of this study. However, due to sample degradation, n = 22 participants were included in this
study.
Results
Sample demographics. Twenty-two men (mean age = 65.86 + 6.87 years) were
included in the study. All participants were able to carry on all pre-disease activities without
restrictions, based on their Karnofsky performance scores (Johnson et al., 2014). Table 1
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describes the demographic and clinical characteristics of the sample. About 70% of participants
had Gleason
scores of 7 (31.82%) or 8 (36.36%). About 70% of participants had a clinical t-stage (Cheng et
al., 2012) of T1c (22.72%), T2a (27.27%), or T2c (22.72%), indicating that most participants had
disease that had not spread outside the prostate gland. Participants received EBRT five days a
week; 17 participants received a total dose of 75.50 Grays for 42 days, while 5 participants who
had prior prostatectomies, received 68.40 Grays of EBRT for 38 days.
Table 1. Demographic and Clinical Characteristics of Sample
Variable
Age
Race
White
A.A./Black
Hispanic
Ethnicity
Hispanic/Latino
Not Hispanic/Latino
Gleason
Clinical T-Stage
T1c
T2a
T2b
T2c
T3a
T3b
PSA(0-3.99 ng/mL)
Testosterone (181-758 ng/dL)
WBC (4.23-9.07 K/µL)
RBC (4.63-6.08 M/µL)
Hemoglobin (13.70-17.50 g/dL)
Albumin (3.70-4.70 g/dL)
Body Mass Index (18.50-24.90)

Mean (SD)
65.86 (6.87)

n (%)

Median (Range)

16 (72.73)
4 (18.18)
2 (9.09)
3 (13.64)
17 (77.27)
Disease Characteristics
7.59 (.91)
5 (22.72)
6 (27.27)
2 (9.09)
5 (22.72)
1 (4.55)
1 (4.55)
Pre-EBRT Levels
3.69 (5.24)
220.37 (166.02)
6.13 (1.67)
4.61 (0.44)
13.95 (12.80-15.60)
4.10 (2.70-4.40)
29.85 (22.90-40.70)

SD = standard deviation, A.A. = African American, T-stage = tumor stage (TNM classification for tumor staging),
PSA = prostate specific antigen, WBC = white blood cell, RBC = red blood cell
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Fatigue. The median fatigue score on the FACT-F at baseline was 47.50 (range 28.0052.00) and at treatment completion was 43.00 (range = 20.00-52.00); lower scores on the FACTF indicate higher fatigue. The median score on the rPFS at baseline was 0.93 (range = 0-4.41)
and at treatment completion was 3.68 (range = 0-6.73); higher scores on the rPFS indicate more
fatigue.
There was a significant change in fatigue scores detected on both instruments from
baseline to the completion of EBRT for the total sample (FACT-F p = 0.02; rPFS p = 0.004).
There was no significant difference in the change in FACT-F scores from baseline to completion
of EBRT between subjects who received 38 versus those who received 42 days of treatment (p =
0.24). Although the change in rPFS scores over time was significant, the actual change in the
level of fatigue was not considered to be clinically relevant, given that significant fatigue for the
rPFS is defined as a score of > 6 (Piper et al., 1998). In contrast to scores on the rPFS, the change
in FACT-F scores over time was both statistically and clinically significant.
Participants were grouped into those with a clinically significant increase in fatigue from
baseline to completion of EBRT (n = 12) and those who did not have a clinically significant
increase (n = 10). Within the high fatigue group there was a significant decrease in FACT-F
scores from baseline (median = 48.00 [range = 28.00-52.00]) to completion of EBRT (median =
35.50 [range = 20.00-46.00], p = 0.002), while there was no significant change in median FACTF score from baseline (44.00 [range = 30.00-52.00]) to completion of EBRT (47.50 [range =
41.00-52.00], p = 0.12) in the low fatigue group. Table 2a describes the fatigue and HRQOL
characteristics of the all participants and Table 2b describes the fatigue characteristics for those
with high versus low fatigue scores.
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Table 2.
2a. Fatigue and HRQOL Scores for all Study Participants

Fatigue
median (range)
HRQOL
Mean (SD)

Changes in Fatigue and HRQOL Scores during EBRT
n
Baseline
Last day of Treatment Range
rPFS
22
0.93 (0-4.41)
3.68 (0-6.73)
0-10
FACT-F
22
47.50 (28-52)
43.00 (20-52)
0-52
FACT-P

19

132.79 (12.85)

123.74 (18.24)

p-value
0.004
0.02

0-156

0.003

2b. Fatigue Scores for those with High versus Low Fatigue
Changes in FACT-F Scores of High and Low Fatigue Groups during EBRT
Baseline
Last day of Treatment
n
Range p-value
Median (Range)
Median (Range)
High
12
48 (28-52)
35.5 (20-46)
0-52
0.002
FACT-F
Low
10
44 (30-52)
47.50 (41-52)
0-52
0.12
HRQOL= health-related quality of life, EBRT = external beam radiation therapy, SD = standard deviation,
FACT-F= Functional Assessment of Cancer Therapy-fatigue subscale, FACT-P = Functional Assessment of Cancer
Therapy-Prostate questionnaire

HRQOL. The mean FACT-P score at baseline was 132.79 (SD = 12.85) and at
completion of EBRT was 123.74 (SD = 18.24); lower scores on the FACT-P indicate lower
HRQOL. This was a significant decline in HRQOL from baseline to completion of treatment (p
= 0.003). At the completion of EBRT, the HRQOL of the participants was below the
standardized HRQOL score of 126.30 for the general population on the FACT-P (Wei et al.,
2002). There was a significant decline in HRQOL from baseline (mean = 132.78, SD = 10.05) to
completion of treatment (mean = 118.44, SD = 17.11, p = 0.01) in those with high fatigue. In
contrast, there was no significant decline in HRQOL from baseline (mean = 132.80, SD = 15.50)
to completion of EBRT (mean = 128.50, SD = 18.75, p = 0.12) in the low fatigue group.
Mitochondrial measures. Five mitochondrial enzymes (complex I-V) and one
mitochondrial antioxidant (SOD2) were measured to assess mitochondrial function. There were
no significant changes in the mean optical densities of complex I-IV and SOD2 enzymes from
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baseline to the end of EBRT for the participants as a whole. However, when participants were
categorized into high and low fatigue groups, patterns in the directions of the optical densities of
the mitochondrial enzymes were observed. Table 3 lists each of the mitochondrial enzyme levels
for baseline and at completion of EBRT for the high and low fatigue groups.
Table 3. Mitochondrial Enzymes between High and Low Fatigue Participants
Level of Fatigue
Mean (SE) Observed Pattern
High Fatigue (N=12) Complex I Baseline
-0.05 (0.17)
Increase
Complex I Completion
0.01 (0.14)
Complex II Baseline
-1.35 (0.18)
Increase
Complex II Completion
-1.04 (0.07)
Complex III Baseline
0.14 (0.20)
Increase
Complex III Completion
0.30 (0.19)
Complex IV Baseline
-0.32 (0.08)
Increase
Complex IV Completion
-0.24 (0.12)
SOD2 Baseline
3.12 (0.04)
Decrease
SOD2 Completion
3.11 (0.03)
Low Fatigue (N=10) Complex I Baseline
0.14 (0.13)
Decrease
Complex I Completion
-0.05 (0.13)
Complex II Baseline
-1.34 (0.19)
Decrease
Complex II Completion
-1.35 (0.06)
Complex III Baseline
0.66 (0.12)
Decrease
Complex III Completion
0.34 (0.24)
Complex IV Baseline
-0.15 (0.14)
Decrease
Complex IV Completion
-0.22 (0.13)
SOD2 Baseline
3.04 (0.04)
Increase
SOD2 Completion
3.05 (0.05)

p
0.68
0.93
0.54
0.51
0.79
0.20
0.97
0.16
0.61
0.91

Complex I. For the participant group as a whole, the median mitochondrial enzyme
optical density at baseline was 1.21 (range = 0.10-6.37) and at treatment completion was 0.92
(range = 0.19-15.2). There was no significant change in mean enzyme optical density from
baseline to completion of EBRT (t (21) = 0.57, p = 0.58).
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Complex II. For the participant group as a whole, the median mitochondrial enzyme
optical density at baseline was 0.07 (range = 0-0.14) and at treatment completion was 0.07 (range
= 0.03-0.14). There was no significant change in mean enzyme optical density from baseline to
completion of EBRT (t (12) = -1.38, p = 0.19). There was no significant difference in the mean
complex II optical density between the high and low fatigue groups at baseline, but there was a
significant difference at completion of EBRT (p = 0.01), with the high fatigue group having
higher optical densities.
Complex III. For the participant group as a whole, the median mitochondrial enzyme
optical density at baseline was 2.79 (range = 0.14-17.53) and at treatment completion was 2.19
(range = 0.05-34.67). There was no significant change in mean enzyme optical density from
baseline to completion of EBRT (t (21) = 0.33, p = 0.75). At baseline, there was a significant
difference in the mean Complex III optical density between the groups (t (17.44) = -2.22, p =
0.04), with the low fatigue group being higher than the high fatigue group, but this was not
observed at the last day of EBRT.
Complex IV. For the participant group as a whole, the median mitochondrial enzyme
optical density at baseline was 0.42 (range = 0.21-4.14) and at treatment completion was 0.36
(range = 0.22-6.90). There was no significant change in mean enzyme optical density from
baseline to completion of EBRT (t (21) = -0.14, p = 0.89).
Complex V. A colorimetric change was observed for complex V enzyme; however, the
change was not measurable. A multitude of different serial dilutions were attempted; however,
even completely undiluted cell lysate produced no signal above background after repeated
attempts.
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SOD2. For the participant group as a whole, the median mitochondrial enzyme optical
density at baseline was 1195.19 (range = 696.66-2003.01) and at treatment completion was
1193.72 (range = 685.73-2007.62). There was no significant change in mean enzyme optical
density from baseline to completion of EBRT (t (21) = 0.15, p = 0.88).
Correlations. Significant correlations for the participant group as a whole were observed
between mitochondrial complex II optical density and FACT-F scores at baseline (r = -0.57, p =
0.04), and at completion of EBRT (r = -0.64, p = 0.02). A significant correlation for the whole
sample was also observed between the difference in FACT-P scores from baseline to treatment
completion with difference in levels of complex III (r = -0.64, p = 0.003) and complex IV (r = 0.59, p = 0.01) from baseline to completion of EBRT.
For those in the high fatigue group, significant correlations were observed at baseline
between complex II and FACT-F (r = -0.85, p = 0.01) and HRQOL (r = -0.87, p = 0.01) as well
as between complex III and rPFS (r = -0.69, p = 0.01). Significant correlations were also
observed between the difference in HRQOL from baseline to treatment completion and
mitochondrial enzymes (complex III: r = -0.68, p = 0.05), complex IV: r = -0.79, p = 0.01) from
baseline to treatment completion in the high fatigue group. There were no significant correlations
observed for mitochondrial enzymes and fatigue scores or HRQOL in the low fatigue group.
Discussion
To our knowledge, this is the first report of measures of mitochondrial enzyme function
in relationship to fatigue prior to and at the completion of EBRT in men with prostate cancer.
There were significant increases in fatigue and a significant decrease in HRQOL from baseline to
the completion of EBRT. In the participant sample as a whole, there was no significant change
in mitochondrial function from baseline to completion of treatment. When patients were
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characterized into groups based upon change in level of fatigue from baseline to EBRT
completion, we observed preliminary evidence to support the possibility of distinct patterns
between the groups in mitochondrial enzymes. Low fatigue participants tended to have higher
relative levels of mitochondrial enzymes at baseline compared to the high fatigue participants,
and the enzyme levels for the low fatigue group tended to decrease during therapy. The opposite
was observed in the high fatigue group, such that lower relative mitochondrial enzyme levels
were noted at baseline compared to the low fatigue group, and the enzyme levels tended to
increase during EBRT. Opposite patterns were observed with the relative SOD2 enzyme levels,
such that a decreasing pattern in relative SOD2 levels was noted in the high fatigue group, and an
increasing pattern was observed in the low fatigue group. These preliminary findings suggest that
alterations in energy metabolism may contribute to fatigue intensification during radiation
therapy.
The observed patterns in mitochondrial enzymes between participants with high and low
fatigue levels may signal that there is a difference in energy demands between the two groups.
High fatigue subjects may require more energy to maintain metabolic needs during therapy, thus
driving the increase in mitochondrial ETC enzymes. On the other hand, those in the low fatigue
group had higher baseline mitochondrial enzyme levels, which would in theory, enhance cellular
energy and thereby support their metabolic needs during therapy.
Declines in mitochondrial enzymes and an increase in mitochondrial antioxidant levels
have been reported in cells exposed to radiation therapy (Kam & Banati, 2013; Turrens, 2003;
Yoshida et al., 2012). Reactive oxygen species are a byproduct of energy metabolism, and
antioxidants such as SOD2 are protective agents against oxidative stress resulting from increased
ROS production (Chan, 2006; Turrens, 2003). These preliminary data for the low fatigue group
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revealed a pattern that mirrored the pattern observed in previous studies for radiation exposure -a pattern towards decreased mitochondrial ETC enzymes and increased SOD2 levels. However,
our preliminary data in the high fatigue group was the opposite from what would be expected
with radiation exposure -- mitochondrial ETC enzymes increased in this group and SOD2 levels
decreased. This discrepancy provokes a question as to whether the high fatigue subjects attained
a less ideal EBRT outcome in terms of cancer cell death. We compared the mean PSA of high
(0.26 + 0.0.74) and low fatigue (0.25 + 0.39) participants post-EBRT and found no significant
difference (p = 0.20). These findings suggest the possibility that there is an increase in ETC
enzyme energy metabolism in EBRT-related fatigue, resulting in an increase in ROS production
and a decrease in antioxidant availability. However, further research is necessary to determine
the clinical relevance, if any, of the relationship of high fatigue during EBRT to treatment
outcomes.
Previously published research with persons with chronic fatigue has documented reduced
levels of succinate reductase (complex I), cytochrome-c oxidase (complex IV), and CoQ10
(electron shuttle from complex I and II to complex III), as well as disrupted oxidative stress as
evidenced by decreased levels of antioxidants (McArdle et al., 1996; Kurup & Kurup, 2003a,
2003b). Our findings revealed opposite patterns; relative levels of complexes I and IV enzymes
were increasing, while relative SOD2 levels were decreasing among high fatigue subjects during
EBRT. This discrepancy suggests that unlike chronic fatigue, treatment-related fatigue may
entail a rapid increase in energy demand, requiring an escalation of mitochondrial energy
metabolism. As the fatigue persists or becomes chronic, the compensation mechanism may begin
to fail, exhausting the mitochondria as evidenced by reduction in mitochondrial enzyme levels,
and in turn, resulting in increased ROS and reduced levels of antioxidants. This line of thinking
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is consistent with the mitochondrial ETC decline implicated in aging and various
neurodegenerative diseases (Enns, 2003; Wallace, 1999).
The study also brings attention to the possible associations of complexes II and III with
fatigue intensification and complexes II, III and IV with HRQOL during EBRT. Complex II
dysfunction is often associated with a wide range of clinical manifestations including
neuroendocrine disorders, metabolic issues, and skeletal myopathies, which may explain the
observed relationship between complex II with fatigue and with HRQOL (Ackrell, 2002; Rutter,
Winge, & Schiffman, 2010). Complex III plays a pivotal role in health and disease as it is one of
the primary sites of ROS generation (Koopman et al., 2010; Rigoulet, Yoboue, & Devin, 2011).
ROS production has been associated with many negative health implications (Alfadda & Sallam,
2012) and could explain the observed association between increased complex III (increased
ROS) and decreased fatigue and HRQOL. Complex IV is the final enzyme in the ETC
responsible for the reduction of O 2 to H 2 O (Mimaki, Wang, McKenzie, Thorburn, & Ryan,
2012). Complex III and complex IV deficiencies are often associated with global, multi-systemic
clinical presentations such as those seen in liver failure, renal tubulopathy, myopathy, and
cardiomyopathy (Bénit, Lebon, & Rustin, 2009; Antonicka et al., 2003). The broad nature of
complex IV dysfunction may explain the observed association between complex IV and global
HRQOL. The findings suggest that as mitochondrial enzyme levels increase, HRQOL declines.
This exploratory study identified novel relationships between mitochondrial ETC enzyme
dysfunction, fatigue, and HRQOL prior to and at the completion of EBRT; however, the results
are limited by the small sample size and the exploratory nature of the group comparisons. The
differentiation between high and low fatigue scores on the FACT-F does not control for baseline
fatigue levels; however, there were no differences noted between groups in the baseline fatigue
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scores. Further investigations are warranted to identify specific mitochondrial activities and
structures related to the ETC complexes that may directly influence fatigue and HRQOL using
larger samples and more diverse populations. Additionally, as mitochondrial disorders have a
large genetic component, the epigenetic impact of cancer therapies on mitochondrial DNA and
its potential consequences for behavior need further investigation.
Conclusions
This study explored the association between mitochondrial function, fatigue intensity,
and health-related quality of life in men with prostate cancer receiving external beam radiation
therapy. The most important preliminary finding from this study is the possibility that
mitochondrial respiratory ETC complex enzymes might be related to fatigue intensification
during EBRT. However, confirmatory research with a larger sample is needed. These future
studies will be critical to determine if these preliminary findings are replicable, and if so,
whether there are potential therapeutic targets in individuals at highest risk for fatigue
intensification during EBRT, in order to optimize fatigue management and improve HRQOL.
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Chapter Four

To understand the mechanisms related to etiology of cancer-related fatigue (CRF), this
dissertation research initially focused on understanding how fatigue intensifies immediately after
completion of a localized radiation therapy for a non-metastatic cancer. As a certified oncology
nurse, my interest in CRF primarily stems from my clinical encounters with oncology patients
who battled through this debilitating symptom, sometimes even years after completion of their
cancer treatments. Secondly, CRF is an important, discrete, and approachable problem. Unlike
fatigue associated with other diseases such as chronic fatigue syndrome, fibromyalgia, or
traumatic brain injury, the trajectory of CRF and the potential biological mechanisms can be
monitored from the time of diagnosis, and its triggers, such as stage of disease as well as dose
and type of treatment, can be identified and examined.
The biological pathways responsible for CRF have not yet been established. CRF is
commonly believed to be a multidimensional symptom that involves multiple psychosocial and
physiologic mechanisms (Wang, 2008), with most studies focused on markers of inflammation
such as cytokine levels. However, another plausible mechanism for fatigue is disturbances in
mitochondrial function. With my specific interest in the role of mitochondrial function in CRF,
my first step in this exploration was to conduct a literature review to examine markers of
mitochondrial function that have been shown to be associated with fatigue in order to identify
areas needing further research. The findings from this review provided an empirical foundation
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for my program of research. Based on the findings of this review, an ideal starting point for my
investigation involved the measurement of critical mitochondrial enzymes such as complexes IV and mitochondrial-specific oxidative stress marker before and after radiotherapy.
Using the knowledge gained from the literature review, I developed a proposal to
investigate – a potential association between altered energy metabolism as evidenced by
mitochondrial measures and levels of fatigue – in the oncology population. To my knowledge,
the research that followed is the first to describe the levels of and relationship between
mitochondrial enzyme activity and fatigue prior to and at the completion of external beam
radiation therapy (EBRT) in men with prostate cancer. The primary aim of the research was to
describe levels of biomarkers of mitochondrial function, fatigue, and health-related quality of life
(HRQOL) before and at the completion of EBRT. A secondary analysis was conducted of a
descriptive, longitudinal study, Relationship between Mitochondrial Dysfunction and Fatigue in
Cancer Patients Following External Beam Radiation Therapy that was approved by the National
Institutes of Health (NIH) Institutional Review Board (#10-NR-0128), using a subsample of
twenty-two men with nonmetastatic prostate cancer. There were significant increases in the
levels of fatigue and declines in HRQOL from baseline to the completion of EBRT. However,
there was no significant change in the selected biomarkers of mitochondrial function from
baseline to completion of treatment. This result was unexpected, given the a priori expectation of
declines in mitochondrial enzymes and an increase in the mitochondrial antioxidant. My
hypothesis was based upon the findings of my literature review which showed that in various
fatigued populations, several mitochondrial enzymes involved in oxidative phosphorylation were
significantly decreased with a significant increase in oxidative stress (McArdle et al., 1996;
Kurup & Kurup, 2003a, 2003b; Maes et al., 2009a, 2009b; Segal et al., 2012). Additionally,
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declines in mitochondrial enzymes and an increase in mitochondrial antioxidant levels have been
reported in cells exposed to radiation therapy (Yoshida, Goto, Kawakatsu, Urata, & Li, 2012).
Given the exploratory nature of the study, the dissertation research team decided to further
investigate the patient sample to understand the relationship of fatigue and mitochondrial
function in a well-characterized fatigue phenotype. We decided to categorize the participants into
those who developed fatigue intensification and those who did not develop fatigue intensification
during EBRT. The fatigue categories were based upon a cut-score of a greater than or equal to
3-point decrease in the Functional Assessment of Cancer Therapy-Fatigue subscale (FACT-F)
score, which has been shown using this validated measure to represent the minimally important
difference in this fatigue score that requires clinical intervention (Cella, Eton, Lai, Peterman, &
Merkel, 2002).
When patients were characterized into groups based upon change in level of fatigue from
baseline to EBRT completion, there was preliminary evidence to support the possibility of
patterns of mitochondrial enzyme levels between the two fatigue groups; however, these
differences were not statistically significant. Those with non-clinically significant (low) fatigue
had higher relative levels of mitochondrial electron transport chain (ETC) enzymes at baseline
and lower levels of the antioxidant superoxide dismutase 2 (SOD2) at baseline compared to the
clinically significant (high) fatigue participants. Further, the enzyme levels for the low fatigue
group decreased during EBRT. The opposite was observed in the high fatigue group, such that
lower relative mitochondrial ETC enzyme levels and higher antioxidant levels were noted at
baseline in comparison to the low fatigue group, and the enzyme levels increased during EBRT.
Opposite patterns were observed with the relative SOD2 enzyme levels, such that a decreasing
pattern in relative SOD2 levels was noted in the high fatigue group, and an increasing pattern
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was observed in the low fatigue group from baseline to completion of EBRT. These preliminary
findings suggest that alterations in energy metabolism may contribute to fatigue intensification
during radiation therapy. However, replication with a larger sample is necessary. Although our
preliminary evidence was not statistically significant, the results of this dissertation study need to
be replicated in light of the potential clinical implications of mitochondrial activity and CRF.
The plans for the continuation of this program of research encompass a three-part
trajectory: a clinically based inquiry, an animal model, and cell-based investigation. The future
clinical research arm of my program of research will include replication of the dissertation
research with a larger sample size of the same clinical population of men with non-metastatic
prostate cancer receiving localized radiation therapy. Replication in other cancer populations
(e.g., persons with lung, brain, and breast cancer) receiving radiation therapy will also be needed
to test for the presence of a common physiologic pathway for the etiology of fatigue across
irradiated populations. One such pathway might involve the association between mitochondrial
dysfunction, inflammation, and neurodegenerative pathways.
Investigation of the upstream pathway of genes encoding the mitochondrial complexes
that correlated with fatigue in the dissertation findings would also be an important project to
pursue, especially genes encoding complex II, which was significantly correlated with fatigue
scores at baseline and at completion of EBRT. This upstream investigation would require the use
of genomic and epigenetic platforms. Cancer and cancer therapy have been observed to initiate
genetic and epigenetic modifications, such as deoxyribonucleic acid (DNA) methylation changes
(Dobosy, Roberts, Fu, & Jarrard, 2007; Li, Carroll, & Dahiya, 2005). Wang et al. (unpublished
data) from the NINR lab recently observed loss of DNA methylation in the promoter region of
genes encoding a mitochondrial function-related gene for which expression was significantly
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associated with fatigue during EBRT in men with prostate cancer. These epigenetic
modifications may be reversible through lifestyle remodeling, an important implication for the
role of nursing interventions for those with cancer (Alegría-Torres, Baccarelli, & Bollati, 2011).
Further, investigating the functional activity of the mitochondria to see if active
mitochondrial respiration dysfunction is associated with fatigue during cancer therapy is worth
pursuing. Aligning with mitochondrial experts at the National Institute of Nursing Research,
Virginia Commonwealth University, and the University of Florida who can provide mentorship
and opportunities in developing skills required to observe actively respiring mitochondria will be
a crucial next step.
The goal of my program of clinical research is to identify a biomarker of mitochondrial
function that relates to the development of fatigue during radiation therapy. Ultimately,
identification of the biologic mechanisms underlying CRF can lead to the development of
potential therapeutic targets. Future animal and cell-based studies will be incorporated into my
research trajectory to enable enhanced mechanistic investigations of the etiology of CRF. In the
near future I will replicate the dissertation procedures in a murine model to determine samplespecific central and peripheral markers that may establish the relationship of mitochondrial
function and fatigue, using genomic and proteomic approaches. This animal investigation may
assist in plotting important central and peripheral neuromuscular circuits that influence the
development or intensification of fatigue behaviors in the animals. If therapeutic targets can be
identified in the murine model of radiation-related fatigue, then therapeutic manipulations can be
explored to potentially mitigate the fatigue response.
In clinical practice, vitamin supplements such as riboflavin B2, niacin B3, vitamin E and
other mitochondrial cofactors including levo-carnitine, lipoic acid, and acetyl-l-carnitine are used
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as supplemental treatment for mitochondrial disorders in order to enhance either ETC enzyme
activity or antioxidant defenses (Cohen, 2000). The efficacy of these vitamins and mitochondrial
cofactors as treatments for mitochondrial disorders remain controversial and more research is
needed, especially concerning the benefit of these supplements in an oncology population
(Cohen, 2000). The mouse model will be essential to determine the effects of these therapies on
mitochondrial function and fatigue prior to translation to human trials.
The cell-based model will be equally important to enhance exploration into the
mechanisms involved in CRF. The cell-based models will be utilized to provide a deeper
understanding of the effects of radiation on the body. It has been widely reported that
inflammation plays a role in CRF (Bower & Lamkin, 2013). Monocytes and other cell lines can
be irradiated, cultured, and manipulated in various ways to replicate inflammatory responses in
humans during radiation treatment. Additionally, the mitochondrial activity within these
irradiated monocytes can be investigated to determine the effect of radiation on the mitochondria
in this inflammatory cell.
This planned program of research is designed to enhance understanding of the biomarkers
of mitochondrial dysfunction that might contribute to fatigue. This program utilizes a threemodel approach to maximize the knowledge that can be gained and the skills that can be
acquired to answer this important research question. Understanding the mechanisms behind
CRF will ultimately enable identification of therapeutic targets and treatment strategies that can
improve health-related quality of life of oncology patients.
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Appendix

The following measures will be used for the proposed study and are standardized forms that are
validated. All measures have been completed by participants and data confidentially stored.
1. Sociodemographic Data Sheet
2. revised Piper Fatigue Scale
3. Functional Assessment of Cancer Therapy- Fatigue subscale
4. Functional Assessment of Cancer Therapy-Prostate
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